University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2022

Investigation Of Metabolism And Autism-Relevant Behaviors In
Drosophila Lacking Neurexin-1
Kyra Alexandra Levy
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Genetics Commons, and the Neuroscience and Neurobiology Commons

Recommended Citation
Levy, Kyra Alexandra, "Investigation Of Metabolism And Autism-Relevant Behaviors In Drosophila Lacking
Neurexin-1" (2022). Publicly Accessible Penn Dissertations. 4708.
https://repository.upenn.edu/edissertations/4708

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/4708
For more information, please contact repository@pobox.upenn.edu.

Investigation Of Metabolism And Autism-Relevant Behaviors In Drosophila
Lacking Neurexin-1
Abstract
Autism is a neurodevelopmental condition that is highly heterogeneous in its clinical presentation. In
addition to differences in social interaction and communication, and the presence of restrictive, repetitive
behaviors, metabolic dysfunction is becoming more widely known and studied as a co-occurring
condition seen in autistic individuals. However, the etiology of these metabolic alterations in autism
remains unclear. Here, we utilized a combination of metabolomic, physiological, and behavioral assays to
investigate how disruption of the autism-risk gene, neurexin-1, influences energy metabolism and
associated behaviors in Drosophila melanogaster. These analyses revealed that Drosophila lacking
neurexin-1 expression exhibit decreased resistance to environmental stressors, specifically starvation
stress and heat stress. These findings lead us to consider whether the neurexin-1 mutant flies have an
altered metabolic status, thus we performed metabolomics and complementary colorimetric assays and
found that these flies have a distinct metabolic profile, with decreased lipid and carbohydrate stores.
Moreover, neurexin-1-null Drosophila exhibit decreased levels of NAD+, an important cofactor in many
energy production pathways. Interestingly, loss of neurexin-1 also results in disruptions in mitochondrial
morphology in Drosophila flight muscle, in addition to decreased flight ability. Finally, we observed
mechanically-induced seizure-like activity in the neurexin-1 mutant flies, which closely mimics clinical
data wherein patients with deletions in Neurexin-1 experience seizures. Together, these findings point to a
novel role for neurexin-1 in the regulation of energy metabolism and autism-related behavioral phenotypes
in Drosophila, in addition to providing a foundation for further investigation into the etiology of metabolic
dysfunction and seizures in autism.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Neuroscience

First Advisor
Thomas A. Jongens

Keywords
Autism, Drosophila, Metabolism, Neurexin-1, Seizures

Subject Categories
Genetics | Neuroscience and Neurobiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4708

INVESTIGATION OF METABOLISM AND AUTISM-RELEVANT BEHAVIORS IN DROSOPHILA
LACKING NEUREXIN-1
Kyra Alexandra Levy
A DISSERTATION
in
Neuroscience
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2022
Supervisor of Dissertation
_____________________
Thomas A. Jongens, Ph.D.
Associate Professor of Genetics

Graduate Group Chairperson
_____________________
Joshua I. Gold, Ph.D.
Professor of Neuroscience

Dissertation Committee
Marc V. Fuccillo, M.D., Ph.D., Assistant Professor of Neuroscience
Amita Sehgal, Ph.D., John Herr Musser Professor of Neuroscience
Matthew S. Kayser, M.D., Ph.D., Associate Professor of Psychiatry
Aalim M. Weljie, Ph.D., Associate Professor of Pharmacology

ACKNOWLEDGMENT
Throughout my time at Penn, I have been supported and encouraged by so
many people, without whom earning a PhD would not have been possible. I would first
and foremost like to thank my advisor, Tom Jongens, for his unwavering support and
enthusiasm throughout my PhD. Tom is the kind of mentor who celebrates exciting, new
pieces of data, and who is also always available to provide guidance and
troubleshooting ideas whenever experiments may fail. I so appreciated having a mentor
like Tom who was patient, kind-hearted, and who gave me the freedom to explore this
project even though I came to the lab with no prior experience working with flies. I also
must thank Ellie Tarlow, who is a post-doc in the Jongens lab, and who I consider my
second mentor from my time at Penn. Ellie taught me almost everything I know about fly
husbandry, and she was extremely helpful throughout my thesis project and in the
publication of my paper. I am so incredibly grateful to have had someone as kind and
intelligent as Ellie in the lab with me; she has truly influenced who I have become as a
scientist, serving as a role model for scientific rigor and critical thinking. Often it was just
the two of us in the lab, and Ellie made it a fun and welcoming place to be, and I always
enjoyed being there to gab about our daily lives together.
I also want to thank my thesis committee, Marc Fuccillo, Matt Kayser, Amita
Sehgal, and Aalim Weljie. Their feedback on my data was insightful and incredibly
helpful, and our discussions helped me to think more critically about my data and design
experiments that would drive the project forward. I would also like to thank the Sehgal
lab, which is next door to the Jongens lab, and whose members were incredibly

ii

generous and helpful if I ever needed additional fly stocks or wanted to learn a new
assay from their lab.
I owe a huge debt of gratitude to my parents, Carol and Sandy, who have been
my greatest role models throughout my life. They are both scientists as well, so
whenever I called to tell them about my experiments, they were always excited and
curious to hear how one tests for behavioral phenotypes in tiny fruit flies. They have
supported me and cheered me on every step of the way, and I couldn’t be more grateful
for them. Lastly, I need to thank my husband, Jerry. For the past decade, Jerry has been
by my side through my entire journey in higher education, and he has been my source of
joy and comfort through it all.

iii

ABSTRACT
INVESTIGATION OF METABOLISM AND AUTISM-RELEVANT BEHAVIORS IN
DROSOPHILA LACKING NEUREXIN-1
Kyra A. Levy
Thomas A. Jongens

Autism is a neurodevelopmental condition that is highly heterogeneous in its
clinical presentation. In addition to differences in social interaction and communication,
and the presence of restrictive, repetitive behaviors, metabolic dysfunction is becoming
more widely known and studied as a co-occurring condition seen in autistic individuals.
However, the etiology of these metabolic alterations in autism remains unclear. Here, we
utilized a combination of metabolomic, physiological, and behavioral assays to
investigate how disruption of the autism-risk gene, neurexin-1, influences energy
metabolism and associated behaviors in Drosophila melanogaster. These analyses
revealed that Drosophila lacking neurexin-1 expression exhibit decreased resistance to
environmental stressors, specifically starvation stress and heat stress. These findings
lead us to consider whether the neurexin-1 mutant flies have an altered metabolic status,
thus we performed metabolomics and complementary colorimetric assays and found that
these flies have a distinct metabolic profile, with decreased lipid and carbohydrate
stores. Moreover, neurexin-1-null Drosophila exhibit decreased levels of NAD+, an
important cofactor in many energy production pathways. Interestingly, loss of neurexin-1
also results in disruptions in mitochondrial morphology in Drosophila flight muscle, in
addition to decreased flight ability. Finally, we observed mechanically-induced seizureiv

like activity in the neurexin-1 mutant flies, which closely mimics clinical data wherein
patients with deletions in Neurexin-1 experience seizures. Together, these findings point
to a novel role for neurexin-1 in the regulation of energy metabolism and autism-related
behavioral phenotypes in Drosophila, in addition to providing a foundation for further
investigation into the etiology of metabolic dysfunction and seizures in autism.
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CHAPTER 1: INTRODUCTION

Summary
Autism spectrum disorder (ASD), henceforth “autism”, is a heterogeneous
neurodevelopmental condition that is highly heritable and affects about 1 in 44 children
in the United States of America (1–4). Autism is typically characterized by differences in
social interaction and communication, as well as the presence of restricted, repetitive
behaviors and/or interests. Along with these main defining factors of autism, there are
also several co-occurring mental health conditions and medical disorders that are
commonly seen in the patient population. For example, autistic individuals are at an
increased risk for sleep disorders, seizures, and anxiety (5–15). In addition to these cooccurring disorders, it is becoming more widely known in the field that metabolic
disturbances are also common in autistic individuals (16–29). Despite increasing
evidence that alterations in energy metabolism and mitochondrial functioning are altered
in autism, the etiology of these metabolic disturbances remains unclear. Additional
investigation is necessary to better understand the etiology of altered energy metabolism
in autism, and how these alterations may exacerbate or contribute to other co-occurring
disorders in autism.
In this chapter, I will describe the various disorders and conditions seen in the
clinical autistic population. Additionally, I will introduce the gene, Neurexin-1 (NRXN1),
which has been previously implicated in the pathophysiology of autism and other
neuropsychiatric conditions. I will further describe the evidence implicating a role for
NRXN1 in autism and other neuropsychiatric disorders, as well as recent studies in
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animal models that also shed light on how NRXN1 contributes to alterations in neuronal
circuits and behavioral outputs in autism.

Clinical presentation of autism
In his renowned 1943 paper “Autistic Disturbances of Affective Contact,” Leo
Kanner provided one of the first systematic accounts of the core features of autism (30).
He described in detail the clinical presentations of 11 children who exhibited language
impairments, social communication and interaction deficits, restricted interests, and
stereotyped and repetitive behaviors. To this day, these characteristics that Kanner
described are used as the core diagnostic criteria for autism in the Diagnostic and
Statistical Manual of Mental Disorders, 5th Edition (DSM-5). It has become clear in the
field since these early descriptions that clinical presentations of autism are highly
heterogeneous, ranging in severity, developmental trajectory, and the presence or
absence of co-occurring conditions. For example, some individuals may exhibit severe
impairment and intellectual disability (ID), while others may have above-average
intelligence and achieve great academic and occupational success.
The current standard of care for determination of an autism diagnosis is complex,
because just as autism is heterogeneous in phenotype, it is also heterogeneous in
genotype. Whereas in monogenetic disorders such as Fragile X syndrome, tuberous
sclerosis, neurofibromatosis type I, Rett Syndrome, and Down Syndrome, there is a
recognized genetic cause for autism, in idiopathic cases of autism there is usually no
known genetic cause. Thus, diagnosing autism is complicated as there is no universal
genetic test that can be performed, and therefore diagnosis must be made based on
behavioral presentation. The two main components that clinicians use in the diagnostic
2

process are a comprehensive developmental history and an observation of an
individual’s interactions with others. To be diagnosed with autism, an individual must
meet several criteria for social communication deficits, and restrictive and repetitive
behaviors that are outlined in the DSM-5. Specifically, an individual must meet all 3
criteria for deficits in the social communication and social interaction domain, including
difficulties in social emotional reciprocity, nonverbal communication, and developing and
maintaining relationships. Additionally, an individual must exhibit at least 2 out of 4 types
of restricted and repetitive behaviors or interests, which could include stereotyped
speech, repetitive movements, rigid adherence to routines, etc. The DSM-5 also
includes a new criterion for sensory anomalies, such as hyper- or hypo-sensory
responsiveness and sensation-seeking within the “restrictive and repetitive behaviors”
domain. Under the DSM-5, autism can now be diagnosed based on both current and
past symptoms of an individual, which allows clinicians to diagnose autistic individuals in
mid-childhood, adolescence, or even adulthood when symptoms may fully manifest.
Generally autism is estimated to be four times more common in males than in
females (1), but it is thought that this estimate may be inaccurate and the true male-tofemale ratio may be much lower, as females tend to go undiagnosed for autism. In fact,
a recent study suggests that the true male-to-female ratio is 3:4, with females actually
accounting for a greater number of autism diagnoses (31). This study also estimates that
about 80% of autistic females remain undiagnosed at age 18 (31). While the reason for
the underdiagnosis of females remains debated, there are two emerging theories as to
why males are more commonly diagnosed with autism than females. One theory is
called the female protective effect theory, which proposes that autism is less likely in
females because females may require a greater genetic and/or environmental risk to
3

exhibit the same degree of autistic traits that as their male counterparts (32). In essence,
females are at a lower risk for developing autistic characteristics due to some protective
factor. Evidence for this hypothesis has been mixed, and a specific protective factor, be
it a gene on the X chromosome or differences in hormone levels, has yet to be
conclusively identified (33). The second theory is that females are less likely to be
accurately diagnosed with autism compared to their male counterparts, possibly due to
potential “camouflaging,” which is the conscious or unconscious use of strategies to
minimize the appearance of autistic traits in a social setting (33,34). This is especially
true for females without ID (35). Autistic females may exhibit behaviors that are
qualitatively different than the typical male presentation, which is primarily what current
diagnostic criteria are based upon. Thus, females may be less likely to meet these
criteria despite showing clinically significant traits (36). For clinicians who are assessing
for an autism diagnosis, it is critical to understand the vast heterogeneity of the condition
and how it may present differently across individuals to strive for accurate diagnosis.

Co-occurring conditions in autism
In addition to the aforementioned core symptoms exhibited by autistic individuals,
there is also a variety of other co-occurring psychiatric or neurological conditions that are
commonly seen in autism. For example, attention-deficit/hyperactivity disorder (ADHD),
depression, gastrointestinal issues, anxiety, sleep disorders, and epilepsy are fairly
prevalent in autistic individuals. Strikingly, it has been estimated that almost 70% of
autistic individuals experience at least one co-occurring disorder, and nearly 40% may
have two or more psychiatric disorders (37). It is important that these co-occurring
conditions are recognized in an autistic individual, as there is potential for these medical
4

conditions to exacerbate other behavioral problems. For example, autistic children with
poor sleep quality also show lower performance on social cognition and social
communication skills compared to autistic children without sleep disturbances (38).
Thus, it is imperative that clinicians identify potential co-occurring conditions in autistic
patients, as the treatment of these disorders can lead to considerable improvement in
the quality of life for the autistic individual. The following sections will discuss anxiety,
epilepsy, and metabolic dysfunction in autism in greater detail as they are relevant to the
findings presented in Chapter 2.

Anxiety
Anxiety disorders are one of the most common mental health disorders
associated with autism (10–12,39), and they are typically characterized by intense and
excessive worry or fear about everyday situations and can interfere with daily life.
Furthermore, stress has been found to correlate with anxiety levels in autistic individuals
(10). Particularly, increased anxiety in autistic people lowers the tolerance or ability to
cope with everyday stressors, such as change, anticipation, sensory stimuli, and
unpleasant events (10). It is estimated that just under 50% of all autistic people have
experienced an anxiety disorder at some point in their lives (15,40). In autistic children, it
has been found that about 40% had at least one comorbid anxiety disorder, with the
most common being specific phobia, which is an intense and irrational fear of a specific
object or situation (40). In autistic adults, there is about a 42% lifetime prevalence of
anxiety disorders, with obsessive-compulsive disorder and social anxiety disorder being
the most common (15,40). Increased levels of anxiety in autistic individuals may intensify
social difficulties that are typically associated with autism; for example, social anxiety
5

disorder may contribute to avoidance of social situations and promote further social
isolation and additional social difficulties (12,41). Additionally, increased anxiety is also
predictive of poorer quality of life (12,40). Thus, it is crucial to better understand how the
core symptoms of autism and co-occurring anxiety may interact in order to better inform
targeted clinical treatments.

Epilepsy
Epilepsy is a neurological disorder that causes unprovoked, recurrent seizures.
During a seizure, there is a rush of abnormal neural activity, and a person can
experience convulsions, abnormal behavior and sensations, and sometimes loss of
consciousness. Estimates of the prevalence of epilepsy in autistic individuals have
varied in the past, likely due to differences in methodology, such as sample size, age
and sex of the participants, and whether patients with ID were included in the sample.
Despite these variations in the literature, it is evident that there is a higher prevalence of
epilepsy in autistic children than in typically developing children, ranging from 5-45% in
children with autism versus 1-2% of children in the general population (9,14,42–44). This
association between autism and epilepsy increases in individuals with ID, especially
among females (45). The co-occurrence of epilepsy in autism is hypothesized to be due
to common pathogenic mechanisms found in both conditions that can result in an
imbalance of excitatory and inhibitory neurotransmission in the brain (14). Normal
excitatory/inhibitory (E/I) balance is sometimes shifted in epilepsy to an elevated E/I
ratio, which results in hyperexcitability in the cortex and leads to recurrent seizures. This
excitatory/inhibitory imbalance can result from either reduced inhibitory γ-aminobutyric
acid (GABA) neurotransmission, or from increased excitatory glutamate
6

neurotransmission (14). There are various mechanisms by which GABA could be
decreased or glutamate could be increased. For example, disorders in energy
metabolism and mitochondrial functioning have detrimental effects on neurons that have
high firing rates and high energy needs, such as GABAergic interneurons, which in turn
leads to decreased inhibitory neurotransmission and therefore an increased E/I ratio
(14,46). Metabolic disorders can also lead to increased glutamate transmission. For
example, both urea cycle defects and phenylketonuria can lead to increased
extracellular glutamate or increased glutamate receptor density, respectively (47). With
these findings in mind, it is unsurprising that children with both mitochondrial disease
and autism show a relatively high incidence of seizures, at 41% (18). Treatmentresistant epilepsy is common in individuals with idiopathic autism (48), thus further
research into the shared neuropathological mechanisms underlying epilepsy and autism
could help to guide the development of improved targeted therapeutics.

Metabolic disorders
While autism research has been generally focused on neuropathological findings,
there are recent studies showing striking alterations in peripheral markers of
mitochondrial energy metabolism dysfunction. Mitochondria are known for their critical
role in the production of cellular energy, and they are also involved in cellular
metabolism, intracellular calcium signaling, the generation of reactive oxygen species
(ROS), and apoptosis. Mitochondrial dysfunction can be particularly detrimental to
tissues that have a high energy requirement. For example, the brain consumes about
20% of inspired oxygen at rest despite only accounting for 2% of total body weight (49),
and requires a large amount of adenosine triphosphate (ATP) to execute complex
7

processes such as neurogenesis, neurotransmission, and synaptic plasticity (50–52).
Most neuronal ATP is generated via oxygen-dependent oxidative phosphorylation
(OXPHOS) in the electron transport chain (ETC) within mitochondria, therefore when
mitochondrial energy metabolism is disrupted, neuronal function and survival is at risk.
Given their importance in supporting neuronal function, it is unsurprising that
mitochondria have been implicated in the pathophysiology of neuropsychiatric disorders,
including autism (18,53–57).
Metabolic alterations have been implicated in autism as early as 1969, wherein
Friedman reported phenylketonuria in patients with autistic-like symptoms (58). Later in
1985, Coleman and Blass reported lactic acidosis in 4 autistic patients, suggesting
deficits in carbohydrate metabolism (59). In 1998, Lombard proposed mitochondrial
dysfunction resulting in defective neuronal oxidative phosphorylation as a likely
etiological possibility in autism (57). Since these early reports, there have been a
number of studies utilizing neuroimaging methods and biomarker measurements to
assess for disruptions in mitochondrial bioenergetics in autistic patients. For example,
neuroimaging studies using positron emission tomography (PET) and nuclear magnetic
resonance spectroscopy (MRS) have shown decreased glucose utilization and reduced
ATP levels in the cerebral cortices of autistic individuals (16,17). Additionally, levels of
biochemical markers of mitochondrial dysfunction, such as lactate, pyruvate, alanine,
ubiquinone, and carnitine, are significantly altered in autistic individuals compared to a
control population (18–24,26,60,61). Moreover, it was reported that protein levels of
complexes within the ETC were decreased in the cerebellum, frontal, and temporal lobes
in the brains of autistic children (62). Interestingly, this cohort also exhibited increased
levels of lipid hydroperoxides, a marker for oxidative stress, suggesting that the
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decreased expression of ETC complexes may lead to abnormal energy metabolism and
oxidative stress (62). A follow-up study revealed that complexes I, III, and V displayed
significantly reduced activity levels in autistic patients, providing further support of
mitochondrial deficiency (63).
It has been estimated that the prevalence of mitochondrial disease in autistic
children is 5.0%, which is significantly higher than the ~0.01% prevalence in the general
population (18). In addition to this, it is estimated that over 30% of autistic children have
abnormal levels of biomarkers of mitochondrial function, including elevated lactate, and
altered pyruvate, carnitine, and ubiquinone levels (18). Compared to the general autistic
population, autistic children with co-occurring mitochondrial dysfunction also show an
increased prevalence of developmental regression, seizures, motor delays, and
gastrointestinal abnormalities (i.e. reflux or constipation) (18). Additionally, autistic
individuals with mitochondrial dysfunction exhibit conditions not typically seen in the
general autistic population, such as oculomotor abnormalities, hearing deficits,
dysarthria, ptosis, and hypertonia (64). Interestingly, the male-to-female ratio appears to
be more balanced in this population compared to the general autistic population (18,65).
In a small percentage of autistic individuals with co-occurring mitochondrial
dysfunction, rare pathogenic mutations in mitochondrial DNA or nuclear DNA that
directly affect mitochondrial functioning and/or energy metabolism can be identified (18).
However, the majority of autistic individuals with mitochondrial disease do not have an
identified pathogenic mutation in mitochondrial or nuclear DNA directly impacting
mitochondrial function (18,65). Thus, further investigation is required to better
understand potential mechanisms of how metabolic abnormalities arise in autism in
order to develop improved therapeutic interventions.
9

Metabolic alterations in animal models of autism
In addition to the aforementioned findings in the patient population, studies in
animal models of autism also show evidence of metabolic alterations and mitochondrial
dysfunction. In a mouse model for Rett syndrome, MECP2-null mice exhibit significantly
elevated mitochondrial respiration rates, indicating potential proton leakage across the
inner mitochondrial membrane (66). These mice also show decoupling of mitochondrial
respiratory complexes, impaired redox balance, as well as abnormal mitochondrial
morphology in dendritic spines (66–68). The ubiquitin protein ligase E3A (UBE3A)
deficiency mouse is a model for Angelman syndrome, which is a syndrome that has high
comorbidity with autism and seizures. In UBE3A-null mice, mitochondrial dysfunction
and elevated reactive oxygen species were reported in hippocampal neurons (69,70).
This mouse model also exhibited significantly smaller mitochondria with disruptions in
the cristae (70). In a mouse model for Fragile X syndrome, mice that are lacking the
Fragile X proteins, FMR1 and FXR2, have reduced fat deposits, hypoglycemia, and
increased sensitivity to insulin (71). Correspondingly, a Drosophila model of Fragile X
syndrome exhibits a significantly altered metabolome, reduced triglyceride and glycogen
stores, as well as reduced starvation resistance (72). Additionally, elevated insulin
signaling was observed in this Drosophila Fragile X model, and genetic reduction of
insulin signaling was sufficient to ameliorate circadian alterations and memory deficits in
these flies (73). These findings suggested that insulin misregulation contributes to
circadian and cognitive seen in these flies. Metabolic alterations are also seen in animal
models of neurofibromatosis type 1 (NF1), which is a monogenic cancer predisposition
syndrome resulting from loss of function in the neurofibromin protein (Nf1) that is also
10

characterized by increased susceptibility to neurocognitive impairments, such as
attention-deficit/hyperactivity disorder and autism. For example, Nf1 haploinsufficient
mice have reduced fat mass, increased glucose clearance, and increased insulin
sensitivity (74). Similarly, loss of Nf1 in Drosophila leads to increased metabolic rate,
increased feeding, decreased triglycerides, and altered lipid turnover kinetics (75). In a
model for tuberous sclerosis, Tsc2-deficient neurons and neuron-specific Tsc1
conditional knock-out mice show significantly elevated transcript levels of the
mitochondrial uncoupling protein-2 (Ucp2), indicating increased oxidative stress and
mitochondrial dysfunction (76). Moreover, a recent study of mouse models of Down
syndrome, 16p11.2 deletion syndrome, and Fragile X syndrome demonstrated sexspecific alterations in basal energy metabolism as well as differences in key plasma
metabolites related to the tricarboxylic acid (TCA) cycle (77).
As mentioned previously, a small percentage of cases of autistic individuals who
exhibit evidence of altered energy metabolism and mitochondrial dysfunction can be
attributed to rare mutations in their mitochondrial DNA or from mutations affecting
nuclear loci known to be involved in mitochondrial function. However, the majority of
cases of abnormal energy metabolism in autism cannot be immediately linked to genetic
mutations that directly impact mitochondrial function. Likewise, the above animal models
explore mitochondrial dysfunction following disruption in genes whose protein products
do not directly affect mitochondrial biochemistry, and that have widely varied functions
ranging from tumor suppression to transcriptional and translational repression. In these
cases of “secondary” mitochondrial dysfunction in autism, a mechanism for exactly how
alterations in energy metabolism arise is yet to be fully elucidated. Hypotheses have
emerged in recent years suggesting that pathophysiological triggers, such as increased
11

inflammation and immune dysregulation, excessive intracellular Ca+2 signaling, and
altered cAMP/PKA signaling could lead to impaired OXPHOS and increased oxidative
stress (65,78–80). The brain is more vulnerable to decreased energy production from
OXPHOS and increased oxidative stress than most organs due to its high energy
demands, its relatively low antioxidant enzyme activity, and a high concentration of
polyunsaturated fatty acids in the myelin sheath and cell membranes, which are highly
susceptible to peroxidation (81). To this end, increased oxidative stress leads to tissue
damage and cell death (81). Thus, mitochondrial dysfunction and oxidative stress may
disproportionately disrupt neurodevelopment and synaptic functioning, giving rise to
neuropsychiatric disorders. There are current treatments available for metabolic
disorders, so clarifying how disruptions in energy metabolism arise in autism would help
to inform targeted treatments which could improve physiological function and health in
autistic individuals.

Introduction to NRXN1
Autism has a highly heritable and complex genetic component, with contributions
from alleles of varying frequencies (i.e., common, rare), inheritance patterns (i.e.,
dominant, recessive, X-linked, de novo), and variant type (i.e., chromosomal
rearrangements, copy number variants (CNV), small insertions or deletions, and single
nucleotide variants (SNVs)) (2–4,82). More than 100 genes have been identified that
meet rigorous statistical thresholds for association with autism (83–85). Interestingly, a
significant number of these genes appear to cluster in one of two major areas of biology:
synaptic structure/function and chromatin modification (85–88). Within the synaptic
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structure/function domain, a gene called Neurexin-1 (NRXN1) has been significantly
implicated in the pathophysiology of autism (89–97).
Neurexins were first discovered as a receptor for α-latrotoxin, which is a toxin in
the venom of the black-widow spider (98). Neurexins are cell adhesion molecules that
are primarily expressed by neurons throughout the central and peripheral nervous
systems and are localized at the presynaptic space, where they have a complex role in
synaptic formation and maintenance, and Ca+2-dependent synaptic transmission (89,98–
102). In vertebrates, there are three NRXN genes, NRXN1-3, each of which have
independent promoters for a long isoform and a short isoform, α- and β-neurexins
respectively (98). The neurexin genes are among the largest in the human genome,
consisting of up to 1.62 Megabases (100). Extracellularly, α-neurexins contain 6 LNSdomains (laminin/neurexin/sex-hormone-binding globulin domains) with three
interspersed epidermal growth factor (EGF)-like repeats, followed by an O-linked sugar
modification sequence and a cysteine-loop domain (Figure 1.1, adapted from Tromp et
al., 2021) (99). β-neurexins are transcribed from an internal promoter within α-NRXNs,
and they only have a single extracellular LNS-domain (Figure 1.1). α- and β-neurexins
both have a transmembrane domain, followed by a C-terminal tail that has a PDZbinding motif (Figure 1.1).
A fascinating property of neurexins is their extensive alternative splicing at their
five canonical splice sites (SS1-SS5), resulting in nearly 4,000 neurexin protein isoforms
that are differentially expressed throughout the brain (100,103). Additionally, there is an
sixth splice site, SS6, in NRXN1 and NRXN2 (104). To add to this complexity, individual
neurons exhibit a cell-type-specific expression pattern of neurexin splice forms that is
coordinated in a region-specific manner (105). Alternative splicing also influences the
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affinity of neurexin isoforms for their binding partners, and this differential binding is
thought to comprise a code through which neurexins play a role in the regulation of
synaptic properties and modulation of neural circuits (99). Neurexins have an array of
binding partners, including neuroligins, cerebellins, latrophilins, dystroglycan, leucinerich repeat transmembrane proteins (LRRTMs), C1q-like proteins, and
calcium/calmodulin-dependent serine protein kinase (CASK) (99). Many of these binding
partners, such as neuroligins, LRRTMs, latrophilins, and dystroglycan, have been
implicated in neuropsychiatric disorders as well (99). Extracellularly, neurexin binds to
postsynaptic ligands, such as neuroligins, neurexophilin, dystroglycan, LRRTM, and
cerebellin, in the establishment of trans-synaptic complexes. Intracellularly, neurexins
bind to CASK via the PDZ-domain, which couples neurexin-mediated cell adhesion to
Ca+2 dependent synaptic vesicle exocytosis machinery (106).
Neurexins orthologs are also present in model organisms, such as mice,
Drosophila melanogaster, and Caenorhabditis elegans. In mice, the three neurexin
genes and their protein products are highly conserved, with identical exon/intron
structures and protein structure (100). In invertebrates, such as Drosophila and C.
elegans, there is only a single neurexin gene (100). In C. elegans, there is both a long αneurexin and a short β-neurexin splice form, whereas Drosophila only express an αneurexin (100,107–109). Invertebrate neurexin protein domain structure is identical to
that of vertebrate α-neurexins, however invertebrate neurexin genes differ from
vertebrate neurexins in their intron structures (100). Invertebrate neurexins also differ
from vertebrate neurexins in that they exhibit no apparent alternative splicing (100,108).
Thus, invertebrate model organisms offer a more simplified system in which to study
NRXN1 function and role in the pathophysiology of neuropsychiatric disorders.
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Implication of NRXN1 in autism and neuropsychiatric disorders
Given the role of NRXN1 in synaptic functioning, disruption of the NRXN1 gene
may lead to impaired synaptic transmission and disrupted neural circuitry, resulting in
improper brain function. Demonstrating its critical role at the synapse as well as its
clinical relevance, disruption of NRXN1 has been associated with a number of
neurodevelopmental and neuropsychiatric disorders, such as intellectual disability,
autism, schizophrenia, and epilepsy (89–97,110–119). Although copy number variants
(CNVs), which are duplications or deletions of sections of base pairs in the genome,
have been identified in all three NRXN genes in individuals with neuropsychiatric
conditions, CNVs in NRXN1 are far more common than in NRXN2 and NRXN3. The
NRXN1 gene locus is particularly susceptible to non-recurrent deletions, due to
instability within the NRXN1 gene that leads to chromosomal rearrangements (120). The
most common CNVs seen in clinical cases are heterozygous exonic NRXN1 deletions,
which are frequently in the 5’ end and span the promoter region and first few exons of
NRXN1 (2p16.3), leading to reduced NRXN1α transcripts (121). It is estimated that
NRXN1 CNVs are present in 0.18% of cases of neurodevelopmental and
neuropsychiatric conditions, compared to 0.02% of controls (121–123). Interestingly,
intronic deletions in NRXN1 do not always pose a significant risk for neuropsychiatric
disorders, as their distribution does not differ between patients and population-based
controls (119,121,124). In fact, both intronic and exonic deletions in NRXN1 can be
found in unaffected parents or siblings of autistic individuals, highlighting the variable
penetrance of NRXN1 deletions (122,125). These NRXN1 deletions with reduced
penetrance may require a secondary, independent pathogenic CNV in another autism
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risk gene, or possible exposure to prenatal environmental risk factors to synergistically
disrupt neurodevelopment and reach threshold for a clinical diagnosis (122).
Disruptions in NRXN1 represent a shared risk factor among neurodevelopmental
and neuropsychiatric conditions, such as autism, schizophrenia, intellectual disability,
and epilepsy. Despite this, it is still unclear exactly how deletions in NRXN1 affect its
function and contribute to the pathophysiology of neurodevelopmental and
neuropsychiatric conditions. Further investigation is necessary to elucidate the biological
mechanisms underlying the development of these disorders wherein NRXN1 is affected.

Neurexin-1 murine models
Due to the conserved nature of neurexin-1 between humans and mice, there
have been many studies investigating the effect of homozygous and heterozygous
disruption of neurexin-1 on autism-relevant endophenotypes in mice. These murine
models present the opportunity for the field to establish causal relationships between
Nrxn1-dependent alterations in neuronal processing and altered behavioral outputs.
Missler et al. established the first Nrxn loss-of-function mouse models in 2003, where
they created single, double, and triple Nrxn1α/2α/3α knock-out (KO) mice by deleting the
first exons of α-Nrxns (101). Mice that were missing a single α-Nrxn were viable,
whereas double and triple α-Nrxn KO mice showed difficulty breathing and impaired
post-natal survival, with double KO mice surviving up to a week and triple KO mice only
surviving one day. These findings suggested that at least two intact α-Nrxns are
necessary for survival, and that β-Nrxns do not compensate for the loss of α-Nrxns and
may have distinct functions. Surprisingly, mice lacking all three α-Nrxns showed normal
brain morphology, and synaptic ultrastructure was also normal compared to wildtype
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animals with no differences in synaptic active zone length, vesicle numbers, vesicle size,
or width of the synaptic cleft (101). However, there was a decrease in the density of
inhibitory synapses in triple KO mice, as well as impaired excitatory and inhibitory
synaptic transmission, partly due to impaired Ca+2 influx during action potentials. These
results showed that α-Nrxns couple synaptic Ca+2 channels to synaptic vesicle
exocytosis machinery for neurotransmitter release. Additionally, their findings suggested
that α-Nrxns are not essential for synapse formation, but that they are involved in
regulating synaptic properties (101).
Later in 2009, Etherton et al. investigated electrophysiological and behavioral
alterations in Nrxn1α homozygous KO mice. These mice exhibited reduced excitatory
synaptic transmission in the hippocampus, which mimicked findings of decreased
excitatory/inhibitory balance in other genetic mouse models of autism (126–128). Nrxn1α
KO mice also displayed behavioral phenotypes consistent with cognitive impairments
seen in autism and schizophrenia, such as impaired nest building, increased repetitive
grooming, improved motor learning, and decreased prepulse inhibition of startle
responses which indicates impaired sensorimotor gating and is common in
schizophrenic individuals (127,129). Additionally, Grayton et al. found that homozygous
Nrxn1α KO mice show altered social approach behavior, reduced social investigation,
and decreased locomotor activity in a novel environment (130). Moreover, male Nrxn1α
homozygous KO mice showed increased anxiety, as well as increased aggression
towards adult conspecifics (130). Mice that have heterozygous deletions in Nrxn1α also
exhibit impairments relevant to autism, including altered social behavior (131).
Interestingly, mouse studies have demonstrated that the same Nrxn mutation can
result in differential phenotypes depending on the cell type. For example, conditional
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ablation of all Nrxn isoforms results in different phenotypes in somatostatin-positive
versus parvalbumin-positive interneurons. Despite the fact that these cell types are both
inhibitory and target pyramidal neurons, pan-Nrxn KO resulted in decreased number of
parvalbumin-positive synapses without synaptic transmission dysfunction, whereas
somatostatin-positive synapses showed normal synapse numbers but decreased
synaptic release due to impaired Ca+2 influx (132). This finding supports the idea that
Nrxns perform distinct fundamental roles in different cell types, and that they are not
always functionally redundant (132).
Recent evidence has also demonstrated how neurexin splice forms can
differentially control postsynaptic properties. By using a genetic knock-in approach to
allow for control of neurexin alternative splicing, Aoto et al. showed that alternative
splicing of neurexin-3 at splice site 4 (Nrxn-3 SS4+) selectively controls AMPA receptor,
but not NMDA receptor, trafficking (133). Nrxn3 SS4+ also suppresses AMPA-receptormediated, but not NMDA-receptor-mediated, synaptic responses (134). Conversely,
alternative splicing of neurexin-1 at SS4 (Nrxn-1 SS4+) enhances NMDA-receptormediated, but not AMPA-receptor-mediated, synaptic responses (134). These studies
demonstrate that neurexin splice forms perform differential, nonoverlapping functions to
trans-synaptically control postsynaptic responses. It is clear that neurexins have a
complex role in synaptic specification that is regulated in a circuit-specific manner, and
additional investigation is imperative to better understand how neurexin control of
synaptic properties is regulated and how this system is disrupted in neuropsychiatric
conditions.

18

Neurexin-1 Drosophila models
Despite increasing evidence from mouse models pointing to Neurexin-1 as a key
player in synaptic formation and synaptic transmission, there are some conflicting
findings in these murine models likely due to the complexity of vertebrate neurexins. For
example, the diversity of phenotypes seen in Nrxn1 mutant mice could be due to
compensatory mechanisms of other Nrxns, differential interactions of Nrxn splice forms
with postsynaptic ligands, or possibly due to distinct synapse- and cell-type specific
functions of Nrxns. Thus, these intricacies make it difficult to clearly understand
neurexin-1 function in vivo. Simpler invertebrate systems, such as Drosophila
melanogaster, present a potential solution to this problem as they only express one
neurexin-1 ortholog that does not exhibit alternative splicing (100).
Neurexin IV was the first neurexin-related gene that was identified in Drosophila,
but it is actually only distantly related to neurexins and is structurally identical to
contactin-associated protein 1 (Caspr1), which is a member of the Caspr/paranodin
family and is localized to the septate junctions of glia, epithelia, and ectodermally derived
cells (135,136). Later, the Berkeley Drosophila Genome Project lead to the discovery of
a single gene that encodes a protein with domain structure identical to that of vertebrate
α-neurexins (Figure 1.2, adapted from Li et al., 2007) (100,108,109). This Drosophila
neurexin-1, henceforth Nrx-1, is expressed throughout the central nervous system and is
enriched at the synapse in central and motor neurons (108). Interestingly, Nrx-1 is
expressed both pre- and post-synaptically in Drosophila at the neuromuscular junction
(137,138). In addition to being expressed in the nervous system, Nrx-1 was also
detected in the salivary glands, gut, wings and legs of adult flies (138). Since the
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discovery of this α-neurexin ortholog in Drosophila, there have been several studies
investigating the role Nrx-1 in regulating synaptic properties and behavioral control.
In 2007, Li et al. and Zeng et al. both independently demonstrated striking
alterations in synapse properties in Nrx-1 mutants. Specifically, Nrx-1 mutants exhibited
reduced amount of synapses, abnormal distribution of synaptic vesicle and active zone
proteins as well as postsynaptic density proteins and glutamate receptor clusters
(108,109). Additionally, Nrx-1 mutants showed a detachment of the presynaptic density
from the postsynaptic density, and defective synaptic transmission (109). Several
studies followed in subsequent years that also demonstrated synaptic and
electrophysiological alterations in Nrx-1 mutants (see Table 1.1). These studies support
the role of neurexin-1 as a regulator of synaptic formation and synaptic transmission.
Moreover, Nrx-1 mutant flies exhibit various behavioral phenotypes, such as decreased
locomotor activity, associative learning defects, fragmented sleep, impaired sleep
homeostasis, altered circadian rhythm, and reversal-learning defects (108,109,139–
142). These findings mimic the cognitive impairments and sleep disruptions commonly
seen in autistic individuals (5–7,143–146). Thus, Drosophila Nrx-1-deficient flies exhibit
clinically relevant phenotypes and serve as a powerful, genetically tractable model in
which a detailed investigation into Nrx-1 function can be performed.

Neurexin-1 and energy metabolism
As previously discussed, Neurexin-1 has been identified as a risk gene for the
development of autism, and autism can be accompanied by co-occurring metabolic
dysfunction. Despite this overlap, there is limited evidence implicating a role for
Neurexin-1 in the regulation of energy metabolism. For example, there is evidence
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suggesting that Neurexin-1 may be involved in the regulation of insulin signaling, which
has an important role in energy metabolism, particularly in regulating glucose and lipid
homeostasis (147). It has been shown that neurexins and neuroligins are actually
expressed in vertebrate pancreatic β-cells, which have exocytic machinery that is very
similar to neuronal synapses (148). Interestingly, β-cells were found to predominantly
express neurexin-1α, where it binds to components of the secretory granule-docking
machinery in the regulation of insulin secretion (149). Decreased neurexin-1α expression
in β-cells was shown to increase glucose-stimulated insulin secretion, likely by
decreasing secretory-granule docking which is thought of as a constraint on insulin
secretion (149). These studies overall indicated neurexin-1α as a component of the
exocytotic machinery for insulin granule docking in pancreatic β-cells. Additional
evidence in Drosophila revealed that Nrx-1 interacts with and regulates apolipoprotein I
in the retina (150), which could point to a role for Nrx-1 in the regulation of fatty acid
metabolism, but this has yet to be fully elucidated. Studies of neurexin-1 function have
understandably been focused on its role at the synapse in regulating synaptic
organization and transmission, but the aforementioned findings point to neurexin-1 as
being expressed outside of the brain with unconventional functions. Beyond these
studies, a role for neurexin-1 as a regulator of energy metabolism remains mostly
unexplored. Given the complexity of its differential interactions with binding partners, as
well as its vast expression patterns, it is increasingly possible that Neurexin-1 has a
range of novel, unexplored roles that may impact diverse physiological functions.
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Concluding remarks
Understanding the role of neurexins in the clinical population and in mammalian
animal models has certainly proven to be quite complex. In the clinical autism
population, there is a wide range of symptom severities and developmental trajectories,
making it a highly heterogeneous population. In addition to this, there are also several
co-occurring conditions, such as sleep disruptions, depression, anxiety, gastrointestinal
issues, intellectual disability, and seizures, that may or may not be present in an autistic
individual. It is well known in the field that autism is highly heritable, although the
genetics of the condition are incredibly complex with over 100 risk genes that have been
implicated with contributions from alleles of varying frequencies in the population,
inheritance patterns, and variant types (2–4,82–85). While NRXN1 has been significantly
implicated in autism, it also shows variable penetrance patterns wherein NRXN1
deletions can be found in autistic individuals and their unaffected family members,
suggesting that genetic background may have an influence on clinical presentation in
these individuals. In mouse studies, considerable advances have been made in
understanding the role of Nrxn1 at the synapse, while also highlighting the complexity of
Nrxn function in mammals. For example, it was shown that the same Nrxn mutation can
result in differential phenotypes depending on the cell type (132). Additionally, different
neurexin splice forms can also differentially control postsynaptic glutamatergic receptor
properties (133,134). Additionally, conflicting behavioral phenotypes have been reported
in Nrxn1 mouse models, which could be due to compensatory mechanisms of other
Nrxns, differential interactions of Nrxn splice forms with postsynaptic ligands, or possibly
due to distinct synapse- and cell-type specific functions of Nrxns.
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The aforementioned intricacies in the clinical population and mouse models have
made it a challenge to fully understand how disrupted NRXN1 functioning contributes to
the pathophysiology of neuropsychiatric disorders. The discovery of a NRXN1 ortholog
in Drosophila, Nrx-1, has aided this investigation due to the simpler nature of Nrx-1.
Thus far, findings in the Nrx-1-null flies indicate a crucial role for Nrx-1 in the regulation
of synaptic architecture and synaptic transmission.
While most clinical and pre-clinical studies on the pathophysiology of autism
have focused on neuronal phenotypes, there is an underappreciated cohort of studies
showing metabolic alterations and mitochondrial dysfunction in autistic individuals. Due
to this lack of focus on systemic alterations in autism, it is still unclear how alterations in
energy metabolism arise in autism and how they may exacerbate other clinical
symptoms. In my thesis, I focused on characterizing peripheral metabolic phenotypes, in
addition to related behavioral phenotypes in Drosophila lacking Nrx-1. In Chapter 2, I will
describe my initial approach of assessing Nrx-1 mutant flies’ response to environmental
stressors, namely starvation stress and acute heat stress. I will also discuss how the
results of these experiments lead me to question the metabolic status of the Nrx-1 flies,
which I assessed using metabolomics and complementary biochemical experiments to
further validate my findings. Chapter 2 also provides evidence that the loss of Nrx-1
results in disruptions in mitochondrial morphology, as well as reduced flight ability and
increased seizure-like behavior. The work presented in this thesis comprises a
combination of behavioral, metabolomic, and physiological methods to uncover a novel
role for Nrx-1 in the regulation of energy metabolism and associated behavioral
phenotypes, serving as a foundation upon which future studies can investigate how
alterations in energy metabolism and mitochondrial function contribute to autism.
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Figure 1.1. Protein domain structures of α- and β-neurexins (adapted from Tromp
et al., 20211). α-neurexins have 6 LNS domains and three EGF domains, while βneurexins have one LNS domain. NRXN1 and NRXN3 have six alternative splice sites
(marked with red arrows), while NRXN2 only has five splice sites. β-neurexins share two
common splice sites with α-neurexins, as well as a glycosylated region marked with an
asterisk, a transmembrane region (TMR), and a PDZ domain binding motif near the C
terminus.

1. Figure 1.1 used with permission from Springer Nature
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Figure 1.2. Conservation of Neurexin-1α protein domain structure between
humans and Drosophila melanogaster (adapted from Li et al., 20072).
Drosophila Nrx-1 exhibits identical protein domain structure as human NRXN1α, with 6
laminin/neurexin/sex-hormone-binding globulin (here abbreviated as LamG) domains
and 3 interspersed epidermal growth factor (EGF) repeats. In blue text is the percent
amino acid identity between Nrx-1 and NRXN1α. Overall, Drosophila Nrx-1 is 36-37%
identical to human NRXN1α. SP, signal peptide; LamG, laminin G domain; EGF, EGF
repeat; TMR, transmembrane region; Dm, Drosophila melanogaster; Hs, Homo sapiens.

2. Figure 1.2 used with permission from Elsevier. Figure was modified to exclude
neurexin IV and Caspr1.
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Table 1.1. List of synaptic/electrophysiological and behavioral phenotypes
observed in Nrx-1 mutant Drosophila. Table 1.1 includes several studies in
Drosophila demonstrating synaptic defects as well as behavioral alterations resulting
from loss of Nrx-1. These findings enhance our understanding of the role of Nrx-1 in
synaptic formation and transmission, and how these alterations may lead to disruptions
in autism-relevant behaviors, such as learning and sleep.
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Abstract
While autism is typically characterized by differences in language, social
interaction, and restrictive, repetitive behaviors, it is becoming more well known in the
field that alterations in energy metabolism and mitochondrial function are a comorbid
disorder in autism. The synaptic cell adhesion molecule, neurexin-1 (NRXN1), has
previously been implicated in autism, and here we show that in Drosophila
melanogaster, the homologue of NRXN1, called Nrx-1, regulates energy metabolism and
nutrient homeostasis. First, we show that Nrx-1-null flies exhibit decreased resistance to
nutrient deprivation and heat stress compared to wildtype controls. Additionally, Nrx-1
mutants exhibit a significantly altered metabolic profile characterized by decreased lipid
and carbohydrate stores. Nrx-1-null Drosophila also exhibit diminished levels of
nicotinamide adenine dinucleotide (NAD+), an important coenzyme in major energy
metabolism pathways. Moreover, loss of Nrx-1 resulted in striking abnormalities in
mitochondrial morphology in the flight muscle of Nrx-1-null Drosophila, as well as
impaired flight ability in these flies. Further, following a mechanical shock Nrx-1-null flies
exhibited seizure-like activity, a phenotype previously linked to defects in mitochondrial
metabolism and a common symptom of patients with NRXN1 deletions. The current
studies indicate a novel role for neurexin-1 in the regulation of energy metabolism as
well as uncover a clinically relevant seizure phenotype in Drosophila lacking Nrx-1.

Introduction
Autism spectrum disorder (ASD), henceforth “autism,” is a neurodevelopmental
condition that affects 1 in 44 children in the United States, and is mainly characterized by
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differences in language, socialization, and sensory perception. In addition to these core
symptoms, co-morbid disorders such as sleep disruptions, seizures, and increased
stress and anxiety are also common in autistic individuals (5–14). Furthermore,
alterations in energy metabolism and mitochondrial functioning have been identified in
autistic individuals in several biochemical, anatomical, and neuroimaging studies. For
example, neuroimaging studies using positron emission tomography (PET) and nuclear
magnetic resonance (NMR) spectroscopy have shown decreased glucose utilization and
reduced ATP levels in the cerebral cortices of autistic individuals (16,17). A more recent
meta-analysis found the prevalence of mitochondrial disease in autistic children to be
5.0%, which is much higher than the ~0.01% prevalence in the general population (18).
Additionally, levels of biochemical markers of mitochondrial dysfunction, such as lactate,
pyruvate, ubiquinone, and carnitine, are significantly altered in autistic individuals
compared to a control population (18–24,26,60). Further, there is evidence of enhanced
oxidative stress in autistic patients (27–29,151), which can lead to impairments in
electron transport chain (ETC) activity. In some autistic patients, these abnormalities in
energy metabolism can be explained by mutations in mitochondrial or nuclear DNA;
however, in most cases the cause for abnormal energy metabolism in autistic patients is
unclear.
There is increasing evidence showing that disruptions in the gene, neurexin-1
(NRXN1), are associated with autism (89–97). NRXN1 deletions have also been
associated with other neuropsychiatric conditions such as schizophrenia (117,118).
Interestingly, there is evidence of altered brain energy metabolism in the
pathophysiology of schizophrenia as well (152–154), suggesting a potential shared
mechanism for metabolic deficits between autism and schizophrenia.
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NRXN1 is a synaptic cell-adhesion molecule that is primarily expressed in the
central and peripheral nervous systems and is involved in synaptic function and
transmission (89,99). In vertebrates, there are three NRXN genes, NRXN1-3, each of
which have promoters for an α, β, and γ isoforms. NRXNs are also subject to extensive
alternative splicing, resulting in hundreds of differentially spliced isoforms (100). Thus,
understanding how NRXN1 may be involved in disruptions in energy metabolism in
autism and schizophrenia presents a challenge in vertebrates, with so many different
isoforms of NRXN that may be functioning at the synapse.
Invertebrates such as Drosophila melanogaster only contain a single gene
encoding an α-neurexin, Nrx-1, which is not subject to alternative splicing (100), lending
to a simplified system in which we can study how Nrx-1 may regulate energy
metabolism. Additionally, the Nrx-1 protein has an identical domain structural
organization to vertebrate α-neurexins (100). Researchers studying Nrx-1 in flies have
identified that loss of Nrx-1 expression results in defects at the synapse, including
abnormal pre- and postsynaptic structure, altered bouton number, and impaired synaptic
transmission (109,137,155). Nrx-1-null Drosophila also exhibit behavioral phenotypes
that are pertinent to autism, such as disruptions in sleep and associative learning
(108,140,141). Together, these findings indicate that the Nrx-1 mutant fly model exhibits
physiological and behavioral phenotypes relevant to autism and is a valuable tool to
further investigate how metabolic alterations may contribute to autism.
In this study we show that Nrx-1-null mutants display decreased resistance to
starvation stress and heat stress, which led us to question the metabolic status of Nrx-1null mutants. We demonstrate through metabolomics and complimentary colorimetric
assays that Nrx-1 mutant flies display a shift in metabolic signature, in addition to
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decreased lipid and carbohydrate energy stores. Additionally, we show that Nrx-1-null
Drosophila exhibit increased levels of tryptophan and kynurenine, as well as decreased
levels of nicotinamide adenine dinucleotide (NAD+) and a diminished NAD+/NADH ratio.
Further, Nrx-1 mutants show severe morphological disruptions in flight muscle
mitochondria, as well as impaired flight ability. Lastly, Nrx-1 also exhibit seizure-like
activity following an acute mechanical stimulation, which is reminiscent of clinical data
showing seizures in human patients with NRXN1 deletions (110–116). Together, these
findings illustrate a novel role for Nrx-1 in the regulation of energy metabolism in
Drosophila, as well as identify a clinically relevant seizure phenotype.

Results
Nrx-1 mutants show decreased resistance to starvation and heat stress
We first set out to investigate the role of Nrx-1 in regulating responding to
environmental stress as it relates to stress and anxiety in autism (12). Specifically, we
asked whether Nrx-1-null flies can withstand environmental stressors, in this case
starvation stress and heat stress, compared to iso31Bw- (wild-type) conspecifics. For
these studies, we utilized two null mutant alleles, Nrx-1273 and Nrx-1241 (109), and after
six generation out-crosses with the iso31Bw- strain all homozygous Nrx-1 mutants were
viable. To avoid potential confounds due to age or sex, we limited our studies to 3- to 5day-old male flies.
For our starvation stress experiments, we recorded the survival time of flies of
each genotype on a 2% agar medium. The 2% agar medium, while providing zero
nutritional value, allowed for a source of water and eliminated desiccation as a cause of
mortality. These experiments were performed using the Drosophila Activity Monitoring
32

(DAM) system, and thus we determined the time of death for each fly by identifying the
last recorded activity count. We found that the Nrx-1 mutants died significantly faster
than their wild-type counterparts when deprived of nutrients (Figure 2.1A). As an added
control, we replicated these experiments using transheterozygous Nrx-1273/241 mutant
flies to ensure that the decreased starvation resistance that we observed in the
homozygous Nrx-1 mutants was not due to any extraneous background mutation in
either allele. The Nrx-1273/241 transheterozygotes also exhibited significantly decreased
resistance to starvation stress compared to control flies (Figure S2.1A), indicating that
this increased sensitivity to stressors is a result of loss of Nrx-1. This finding led us to
wonder whether Nrx-1 mutants are hypersensitive to stressors other than starvation
stress, so we also assessed survival of Nrx-1 mutants after heat stress. To measure the
response of the Nrx-1 mutants and controls flies to heat stress, we exposed flies of each
genotype to 37°C for one hour, returned all flies to 25°C after heat exposure, and then
assessed for survival 24 hours later (156). We found that the Nrx-1 mutants had
significantly decreased survival rates following acute high heat exposure (Figure 2.1B).
This finding, combined with our starvation stress experiments, suggested to us that Nrx1 mutants are hypersensitive to environmental stressors, such as nutrient deprivation
and heat stress.
Together, these data show that Nrx-1 mutants have decreased resistance to
nutrient deprivation and heat stress, which indicates potential alterations in energy
metabolism in the Nrx-1 mutants. Survival during starvation has shown to be influenced
by lipid and glycogen content (157,158). Additionally, survival following heat exposure
also has metabolic implications as it has been shown that heat stress causes significant
depletion of metabolites involved in energy metabolism, such as glycogen and
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triglycerides (159–161). Thus, it follows that an organism with an altered metabolic
profile characterized by decreased energy stores would have decreased survival rates
when undergoing nutrient deprivation or heat stress. Therefore, our findings led us to
hypothesize that the Nrx-1 mutants have an altered metabolic profile.

Nrx-1 mutants exhibit metabolic alterations, characterized by decreased lipids and
carbohydrates.
To understand whether altered metabolic homeostasis underlies the decreased
resistance to nutrient deprivation and heat stress in the Nrx-1 mutants, we began with a
broad approach by performing a metabolomics screen of primary metabolite and
complex lipid levels. Six independent samples of 40 whole flies per genotype were
analyzed for primary metabolites and complex lipids by mass spectrometry. From the
resultant datasets we used Principle Component Analysis (PCA) to determine whether
we could segregate the Nrx-1 mutants from their wild-type conspecifics based solely on
their primary metabolite and complex lipid metabolite signature. We found that the PCA
plots for both primary metabolism and complex lipids showed a clear separation of
iso31Bw- from both Nrx-1273/273 and Nrx-1241/241 mutants, while the Nrx-1 mutants still
overlapped with each other (Figure 2.2A-B). These data indicate a significant shift in
primary metabolites and complex lipid metabolites in the Nrx-1 mutants relative to
control animals.
We next performed a more detailed review of the known metabolites that were
significantly altered in both the Nrx-1273/273 and Nrx-1241/241 mutants compared to wildtype flies according to a Mann-Whitney U test with false discovery rate corrected P
value. Within this analysis, we were intrigued to find that all but one of the glycerolipids
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that were included in the analysis were significantly decreased in the Nrx-1 mutants
relative to iso31Bw- controls (Table 1). In contrast, other lipid classes had a mix of lipids
that were increased or decreased in the Nrx-1 mutants. Glycerolipids are a large group
of molecules that includes triglycerides, which represent over 90% of stored lipids in
Drosophila. Importantly, triglycerides have previously been found to be crucial for
survival during starvation and heat stress (157–161). We sought to validate this finding
of decreased glycerolipids by performing an additional colorimetric assay to measure
triglyceride levels in the bodies of Nrx-1 mutants and iso31Bw- controls. We chose to do
these experiments using decapitated bodies only, as opposed to whole bodies, for a few
reasons. First, eye pigment has the potential to interfere with accurate absorbance
measures in these colorimetric assays (162). Second, the primary tissue for the storage
of fuel molecules, such as triglycerides and glycogen, is the fat body in Drosophila.
Additionally, there is important crosstalk between central and peripheral tissues in the
regulation of energy metabolism (163–166). Thus, we were interested in whether loss of
Nrx-1 leads to systemic alterations in nutrient homeostasis. Consistent with the observed
decrease in glycerolipids in our metabolomics experiments, we found that Nrx-1273/273
and Nrx-1241/241 homozygous mutants, as well as Nrx-1273/241 transheterozygous mutants,
exhibit significantly diminished triglyceride levels compared to control animals (Figure
2.2C and Figure S2.1B).
In addition to diminished glycerolipids, our metabolomics experiments also
revealed that Nrx-1 mutants have decreased glucose levels compared to wildtype
conspecifics (Figure 2.2D). While glucose is not the primary insect blood sugar, it is the
precursor for glycogen which is the primary form of carbohydrate storage in Drosophila
(167). As mentioned previously, glycogen content is important for survival during nutrient
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deprivation and heat stress. Given that glucose was decreased in the Nrx-1 mutants, we
sought to uncover whether glycogen was also diminished using a colorimetric assay with
Nrx-1 mutant and wild-type bodies. Consistent with our data showing decreased glucose
levels, these colorimetric experiments revealed that Nrx-1 mutants have significantly
diminished glycogen levels compared to wild-type controls (Figure 2.2E).
Taken together, these findings suggest that Nrx-1 plays a role in the regulation of
lipid and carbohydrate metabolism. While there are several possible hypotheses that
could explain how Nrx-1 may regulate energy metabolism, we first began to gather clues
to these questions by assessing feeding and activity levels in the Nrx-1 mutant flies. To
assess feeding levels, we placed fasted flies on cornmeal-molasses medium that was
spiked with Brilliant Blue FCF, and then performed spectrophotometry on samples from
whole flies to determine the amount of labeled food ingested. For these experiments, we
chose to starve the flies for 18 hours prior to the feeding period as it has been shown
that after prolonged periods of starvation, feeding is driven by taste-independent
mechanisms (168); thus, we can avoid potential confounds due to taste perception. We
ultimately found no significant difference in feeding levels between the Nrx-1 mutants
and their wild-type controls (Figure 2.2F), suggesting that reduced energy stores cannot
be attributed to decreased food intake. Next, we considered the hypothesis that Nrx-1
mutants are hyperactive and thereby burn through their lipid and carbohydrate stores
faster than control flies. To determine daily activity levels of the Nrx-1 mutants, we used
the Drosophila Activity Monitoring (DAM) System. We analyzed our data in terms of
waking activity and average daily activity counts. These measures differ in that waking
activity is a measure of how active a fly is during times of wake, whereas average daily
activity count is a three-day average of the total activity throughout the course of an
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entire 24-hour day. These experiments revealed that both Nrx-1273/273 and Nrx-1241/241
mutants actually display decreased waking activity compared to iso31Bw- controls
(Figure 2.2G). Conversely, in terms of average total daily activity the Nrx-1273/273 mutant
flies exhibit increased total activity counts, and the Nrx-1241/241 flies show no difference in
activity compared to control flies (Figure 2.2H). While the Nrx-1273/273 mutants showed
increased average daily activity (Figure 2.2H) we believe this can be attributed to
decreased and fragmented sleep in these flies lending to more time awake and therefore
an increase in daily activity counts (Figure S2.2). Additionally, the fact that we only see
an increase in average daily activity counts in the Nrx-1273/273 mutants and not the Nrx1241/241 mutants suggests that increased activity alone cannot explain the decreased lipid
and carbohydrates seen in both Nrx-1 mutant alleles. Thus, it appears that decreased
lipid and carbohydrate stores cannot be fully explained by decreased feeding or
hyperactivity, as the Nrx-1 mutants exhibit normal feeding levels and show decreased
waking activity compared to controls. Additionally, these alterations in energy stores
cannot be attributed to body size as the Nrx-1 mutants have similar body weight
compared to controls (Figure S2.3).

Nrx-1 mutants show altered tryptophan, kynurenine, and NAD+ levels.
Our metabolomics studies indicated significant alterations in lipid metabolism and
carbohydrate metabolism in the Nrx-1 mutants, and thus we decided to further examine
this dataset to assess for any additional alterations of components of energy metabolism
(Table S2.2). Interestingly, we found that Nrx-1 mutants exhibited significantly elevated
levels of tryptophan as well as elevated levels of kynurenine according to a MannWhitney U test (Figures 2.3A-B, Table S2.2). Tryptophan is converted to kynurenine in
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the de novo synthesis pathway of nicotinamide adenine dinucleotide (NAD+) (Figure
S2.4). Notably, nicotinamide (NAM), the precursor for NAD+ in the salvage pathway was
unchanged in the Nrx-1 mutants compared to controls (Table S2.3). Moreover, nicotinic
acid (NA), the precursor for NAD+ in the Preiss-Handler pathway, was significantly
increased only in the Nrx-1241/241 mutants and not in the Nrx-1273/273 mutants (Table S2.3).
These findings suggest that there may be dysregulation mainly in the de novo synthesis
pathway of NAD+. NAD+ is a crucial regulator of energy metabolism by functioning as a
coenzyme in redox reactions within the major energy production pathways, including
glycolysis, the TCA cycle, fatty acid oxidation (β-oxidation), and oxidative
phosphorylation (OXPHOS) (169). Based on our findings of dysregulated NAD+
precursors, we decided to assess NAD+ levels in the Nrx-1 mutants. We performed these
experiments using a colorimetric assay with bodies of Nrx-1 mutants and wild-type
controls. Interestingly, we found that the Nrx-1 mutants showed significantly diminished
NAD+ levels (Figure 2.3C), although there were no significant changes in NADH levels
(Figure 2.3D). Additionally, the NAD+/NADH ratio was significantly decreased in the Nrx1 mutants compared to controls, which was likely driven by the decrease in NAD+ levels
(Figure 2.3E). The observed decrease in NAD+ and the NAD+/NADH ratio could
potentially contribute to the metabolic impairments seen in the Nrx-1 mutants, as
diminished NAD+ levels have been shown to be involved in the development of
behavioral, mitochondrial, and metabolic disorders (170–176).
To assess the hypothesis of whether decreased NAD+ levels underlie the
diminished stress resistance in the Nrx-1 mutants, we attempted treating the Nrx-1
mutants with NAD+ precursors, nicotinamide riboside (NR) and nicotinamide (NAM).
Treatment with NR or NAM was not sufficient to improve starvation resistance to wild38

type levels in Nrx-1273/273 and Nrx-1241/241 flies (Figures S2.5 and S2.6). In fact, Nrx-1273/273
flies treated with NAM showed significantly worsened starvation resistance compared to
vehicle treated counterparts (Figure S2.6C). There are several reasons as to why
treatment with NAD+ precursors may have been insufficient to improve starvation
resistance in the Nrx-1 mutants, for example the drug dosage or timing of drug delivery
may not have been optimal for phenotypic rescue. Additionally, it could be possible that
the starvation resistance phenotype in the Nrx-1 mutants is caused by a combination of
factors whereby treatment with NAD+ precursors alone is insufficient for rescue.

Loss of Nrx-1 leads to abnormal mitochondrial morphology and impaired flight.
Our findings thus far closely mimic those seen in a previous study from our lab
which showed diminished lipid and carbohydrate stores as well as decreased NAD+
levels in a Drosophila model of Fragile X Syndrome, which is the leading monogenic
cause of autism (72). This previous study also observed striking morphological
abnormalities within flight muscle mitochondria. Thus, we pondered whether Nrx-1
mutants would exhibit similar morphological alterations in their mitochondria as well. For
these experiments, longitudinal sections of indirect flight muscle in the thorax of Nrx-1
mutants and controls were prepared for transmission electron microscopy. We chose
this section of tissue specifically because the flight muscle requires robust mitochondrial
functioning for its high energy demands. Additionally, this tissue has a structured
organization of mitochondria lining the space in between individual myofibrils, making it
optimal for comparison among conspecifics. In the wild-type animals, we observed
mitochondria that appeared intact, as well as densely packed and regularly distributed
along the muscle fibers (Figures 2.4A and D). Conversely, the mitochondria in the Nrx39

1273/273 and Nrx-1241/241 mutants appeared irregularly spaced between myofibrils (Figures
2.4B, C, E, F). Upon closer inspection using higher magnification, it was clear that
mitochondria in the Nrx-1 mutants also appeared severely damaged with disruptions in
the cristae (Figures 2.4E and F).
Given that mitochondrial ultrastructure and function are closely linked, and that
the observed pathological lesions were within the mitochondria of indirect flight muscle,
we decided to assess flight ability in the Nrx-1 mutants. Consistent with the severely
disrupted ultrastructure found in flight muscle mitochondria in the absence of Nrx-1, we
found that Nrx-1273/273 and Nrx-1241/241 homozygous mutants, as well as Nrx-1273/241
transheterozygous mutants, had significantly weakened flight ability compared to wildtype conspecifics (Figure 2.4G and Figure S2.1C). It is likely that the morphological
abnormalities in flight muscle mitochondria contribute to this decreased flight fitness in
the Nrx-1 mutants. Additionally, glycogen is the energy reserve that is used during flight
in Drosophila (177), and therefore it is possible that decreased glycogen levels in the
Nrx-1 mutants (Figure 2.2E) also contribute to reduced flight ability in the Nrx-1 mutants.
Overall, these findings demonstrate that loss of Nrx-1 gives rise to pathological
disruptions in mitochondria in indirect flight muscle, and importantly that the functional
output of this tissue, flight ability, is disrupted in Nrx-1 mutants.

Nrx-1 mutant flies exhibit seizure-like behavior after mechanical stimulation.
The striking mitochondrial defects that we identified, coupled with multiple reports
in the clinical literature that patients with deletions in NRXN1 exhibit seizures (110–116),
prompted us to assess seizure susceptibility in the Nrx-1 mutants. Mitochondrial
dysfunction has emerged as a primary cause of epilepsy given the critical role of
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mitochondrial OXPHOS in the generation of the ATP required to maintain the proper
balance between excitatory and inhibitory neural transmission (178–181). Given that our
findings thus far are suggestive of potential mitochondrial dysfunction in the Nrx-1
mutants, and that neurexin-1 plays an important role in the regulation of synaptic
function and transmission (99), we hypothesized that Nrx-1 mutants would be
hypersensitive to mechanical shock. To assess for seizure susceptibility, Nrx-1 mutants
and controls were placed in vials and vortexed for 10 seconds (182). These experiments
revealed that following an acute mechanical shock, Nrx-1273/273, Nrx-1241/241, and Nrx1273/241 mutants exhibited a significantly higher percentage of flies showing seizure-like
activity, consisting of hyperactivity, leg twitching, and paralysis, as well as increased time
to recovery after mechanical stimulation compared to control flies (Figures 2.5A and B,
Figure S2.1D-E). These findings indicate that loss of Nrx-1 contributes to seizure-like
activity in Drosophila and are consistent with the clinical data wherein patients with
NRXN1 deletions exhibit seizures.
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Discussion
In our pursuit to better understand how neurexin-1 contributes to the
pathophysiology of autism, we uncovered striking alterations in stress resistance, energy
metabolism, mitochondrial morphology, as well as seizure-like activity following the loss
of Nrx-1 in Drosophila melanogaster. While neurexins are conventionally thought of as
regulators of synaptic properties in the brain (99), our findings suggest that loss of
neurexin-1 also has systemic implications for energy metabolism, which could have a
potential impact on behavior or contribute to the increased prevalence of metabolic
disorders seen in neurodevelopmental disorders, such as autism and schizophrenia.
Here, we show that Drosophila lacking Nrx-1 exhibit decreased resistance to
environmental stress, specifically starvation stress and heat stress. These findings lead
us to investigate the metabolic status of the Nrx-1 mutants using metabolomics and
complementary colorimetric assays, which resulted in the discovery that Nrx-1 mutant
flies have a distinct metabolic profile as well as decreased lipid and carbohydrate stores.
It is likely that these deficient energy stores are underlying the observed decrease in
survival under starvation and heat stress in the Nrx-1 mutants, as reduced energy stores
have been linked to starvation sensitivity and heat stress exposure (157–160).
Interestingly, similar alterations in nutrient homeostasis and energy metabolism have
been revealed in Nrxn1 mutant mice by the International Mouse Phenotyping
Consortium (https://www.mousephenotype.org/data/genes/MGI:1096391) (183), which is
an international effort in phenotyping the 20,000 protein-coding genes in the mouse
genome. Specifically, Nrxn1 mutant male mice were found to have decreased total body
fat, increased lean mass, as well as decreased total cholesterol and HDL-cholesterol
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compared to wild-type controls. These findings are consistent with decreased lipid stores
seen in the Nrx-1 mutant flies. Additionally, female Nrxn1 mutant mice had decreased
fasting circulating glucose levels compared to wild-type animals, which closely mimics
our findings of altered carbohydrate metabolism in Nrx-1 mutant flies. Together, these
findings indicate that both Drosophila and mice lacking neurexin-1 show deficits in lipid
and carbohydrate metabolism, which suggests a potential conserved effect of loss of
neurexin-1 between invertebrates and vertebrates.
Furthermore, the findings presented here are consistent with those of other
animal models of neurodevelopmental disorders that have identified metabolic
differences. Our lab previously demonstrated a significantly altered metabolome,
reduced triglyceride and glycogen stores, as well as reduced starvation resistance in a
Drosophila model of Fragile X Syndrome (72). Additionally, mice mutant for the Fragile X
proteins FMR1 and FXR2 have reduced fat deposits, hypoglycemia, and increased
sensitivity to insulin (71). Metabolic alterations are also seen in animal models of
neurofibromatosis type 1 (NF1), which is a monogenic cancer predisposition syndrome
resulting from loss of function in the neurofibromin protein (Nf1) that is also
characterized by increased susceptibility to neurocognitive impairments, such as
attention-deficit/hyperactivity disorder and autism. For example, Nf1 haploinsufficient
mice have reduced fat mass, increased glucose clearance, and increased insulin
sensitivity (74). Additionally, loss of Nf1 in Drosophila leads to increased metabolic rate,
increased feeding, decreased triglycerides, and altered lipid turnover kinetics (75).
Moreover, a recent study of mouse models of Down syndrome, 16p11.2 deletion
syndrome, and Fragile X Syndrome demonstrated sex-specific alterations in basal
energy metabolism as well as differences in key plasma metabolites related to the TCA
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cycle (77). Our study contributes additional evidence to this growing body of literature,
illustrating dysfunctional energy metabolism as a co-morbid disorder in autism and
suggesting a role for neurexin-1 within this narrative.
The current study provides compelling evidence that Nrx-1 has a role in the
regulation of energy metabolism in Drosophila. However, there are still several
remaining questions as to how this cell adhesion molecule that is primarily thought to
function at the synapse may contribute to broad systemic alterations in nutrient
homeostasis. In Drosophila, Nrx-1 is expressed broadly across the central and
peripheral nervous system, as well as in the muscle, gut, and neuromuscular junction
(108,109,138). Thus, it is possible that Nrx-1 could regulate energy metabolism by
regulating synaptic transmission within a neuronal population that is involved in
metabolic regulation. In Drosophila, the insulin-producing neurons have been shown to
regulate metabolism and are located within the pars intercerebralis region of the brain
(184–188). In vertebrates, NRXN1α regulates insulin granule docking and insulin
secretion via actions in the insulin-producing pancreatic β-cells (148,149). Therefore,
misregulation of the release of Drosophila insulin-like peptides may lead to the observed
metabolic alterations in the Nrx-1 flies. It is well known that there is important
communication between the brain and peripheral tissues in the regulation of energy
metabolism and nutrient homeostasis (163–166), and thus Nrx-1 could be acting cell
non-autonomously to regulate the storage of lipids and carbohydrates within peripheral
tissues. Future studies will be imperative to elucidate the mechanisms by which Nrx-1
regulates the processes presented here.
Beyond the potential routes that loss of Nrx-1 function could alter metabolism
discussed above, the metabolic defects seen in Nrx-1-null flies could also be an effect of
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their diminished NAD+ levels or potential altered mitochondrial function. Given the
importance of an optimal NAD+/NADH ratio in several redox reactions within energy
metabolism pathways such as glycolysis, the TCA cycle, β-oxidation, and oxidative
phosphorylation, the observed decrease in NAD+ levels and the NAD+/NADH ratio could
certainly impact energy metabolism in the Nrx-1 mutants. While we found that NAD+
precursor treatment was not sufficient to rescue starvation resistance, the diminished
NAD+ levels we observed in the Nrx-1 mutants may not be solely explained by
alterations in NAD+ biosynthesis, as the total pool size of NAD+ depends on the relative
rates of synthesis and degradation. In addition to possible alterations in NAD+
biosynthesis, there may be an imbalance in NAD+ consumption due to aberrations in
other metabolic pathways in which NAD+ is a cofactor, which is another possible area of
future investigation. Thus, the failure of NAD+ precursor treatment to rescue starvation
resistance does not provide conclusive evidence that the observed decrease in NAD+
and the NAD+/NADH ratio are not linked to the behavioral phenotypes we see in the Nrx1 mutants, as there are several remaining experiments that are yet to be performed.
Additionally, it would be worthwhile to assess whether NAD+ precursors are able to
improve other metabolic, mitochondrial, or behavioral phenotypes in the Nrx-1 mutants.
Additionally, we also discovered noticeable disruptions and atrophy in the cristae
in mitochondria within the flight muscle of Nrx-1-null flies. In support of the notion that
the observed mitochondrial abnormalities are detrimental to the Nrx-1 mutants, we also
uncovered significantly weakened flight ability in these flies. Again, these findings are in
line with what has been seen previously in a Drosophila model of Fragile X Syndrome,
wherein Fmr1 mutant flies had decreased NAD+ levels and altered mitochondrial
morphology, as well as indications of mitochondrial dysfunction (72). There is increasing
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evidence in mouse models as well supporting the hypothesis that mitochondrial defects
may be central to the etiology of autism and other neurodevelopmental disorders
(67,189–194). Mice with a missense mutation in the mitochondrial DNA complex I ND6
gene exhibit impaired social behavior, increased repetitive behaviors and anxiety,
decreased seizure threshold, as well as alterations in mitochondrial respiratory function
and reactive oxygen species (194). These findings illustrate that altered mitochondrial
function can lead to “autistic-like” phenotypes.
In addition to findings in animal models, there is considerable research showing
evidence of increased prevalence of mitochondrial disease in autistic individuals
compared to the general population, wherein autistic individuals have decreased cortical
glucose utilization and ATP levels, altered levels of biochemical markers of mitochondrial
dysfunction, altered tryptophan levels, as well as increased oxidative stress (16–
29,57,60,65,151,195,196). It will be highly informative for future studies to determine
whether these alterations in NAD+ levels and mitochondrial morphology in the Nrx-1
mutants contribute to potential mitochondrial dysfunction or additional behavioral
phenotypes related to autism.
Furthermore, these studies show that loss of Nrx-1 results in mechanicallyinduced seizure-like activity. These findings are clinically relevant, as patients with
deletions in NRXN1 also exhibit seizures (110–116) and autistic individuals are at an
increased risk for epilepsy, as the average prevalence of epilepsy in autistic children is
12% and reaches 26% by adolescence (13), compared to the less than 1% of children
with epilepsy in the general population. The identification of seizures in the Nrx-1-null
flies illuminates a behavioral paradigm that can be used to assess the efficacy of
potential therapeutic options for autistic individuals who experience seizures. Future
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studies will be crucial to further investigate how loss of Nrx-1 contributes to seizure-like
activity in the Nrx-1 mutants, as these seizures could be the result of altered synaptic
transmission, altered mitochondrial function and bioenergetics, or a combination of these
factors.
While there has been a greater focus on investigating the role of NRXN1
deletions in neurodevelopmental disorders, there is evidence that indicates that
mutations in the paralogous NRXN2 and NRXN3 are also associated with autism and
schizophrenia (197–202). Thus, future studies that examine the extent to which our
metabolic and mitochondrial findings apply to the other members of the NRXN protein
family in vertebrate models would expand our understanding of shared and divergent
features of NRXN1-3.
In conclusion, our work depicts a novel role for neurexins in the regulation of
energy metabolism by using a combination of metabolomic and physiological
methodologies. Moreover, we have identified behavioral alterations in stress resistance,
flight ability, and seizure-like activity resulting from Nrx-1 deficiency. These studies
establish a foundation for future inquiries into the function of neurexins and the role of
metabolic dysfunction in the etiology of autism.
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Figure 2.1. Nrx-1 mutants have decreased resistance to environmental stressors,
such as starvation stress and heat stress. (A) Survival curve of Nrx-1 mutants (red
and blue lines) and wild-type iso31Bw- controls (black line) during starvation. Log-rank
(Mantel-Cox) test with Bonferroni-corrected significance threshold for multiple
comparisons indicated that Nrx-1273/273 and Nrx-1241/241 mutant flies die significantly faster
than wild-type flies when on media containing 0% sucrose and 2% agar. Nrx-1273/273 and
Nrx-1241/241 were not significantly different from each other in starvation resistance.
Sample number (N) per genotype: iso31Bw- N = 64, Nrx-1273/273 N = 61, Nrx-1241/241 N =
58. (B) Survival curve of each genotype 24-hours after an acute heat stress (HS) of
exposure to 37°C for one hour. Log-rank (Mantel-Cox) test with Bonferroni-corrected
significance threshold for multiple comparisons results indicated that Nrx-1273/273 and
Nrx-1241/241 mutant flies have significantly reduced resistance to heat stress compared to
wild-type flies. Additionally, Nrx-1241/241 flies were more sensitive to heat stress than Nrx1273/273 flies. Sample number (N) per genotype: iso31Bw- N = 280, Nrx-1273/273 N = 270,
Nrx-1241/241 N = 270. Values represent mean ± SEM. ** = P <0.01. ****= P<0.0001
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Figure 2.2. Nrx-1 mutants exhibit an altered biochemical signature, with decreased
lipids and carbohydrates. Principal component analysis of (A) primary metabolites and
(B) complex lipids of 3- to 5-day-old iso31Bw- control (red), Nrx-1241/241 (green), and Nrx49

1273/273 (blue) flies reveals a clear shift in (A) primary metabolite concentrations and (B)
lipid levels between the Nrx-1 mutant flies and iso31Bw- flies. Shown are the biplot of
the first two components extracted from a principal component analysis, with point colors
indicating group membership (red= iso31Bw-, green= Nrx-1241/241, blue= Nrx-1273/273) and
normal data ellipses for each group. (C) Quantification of triglycerides in 3- to 5-day-old
adult male flies. Each data point represents an independent sample of 3 fly bodies. Oneway ANOVA with Tukey’s multiple comparisons post-hoc test indicated that Nrx-1-null
mutant flies have decreased triglycerides (P<0.0001) compared to iso31Bw- control flies.
Sample number (N) per genotype: iso31Bw- N= 12, Nrx-1273/273 N = 14, Nrx-1241/241 N =
14. (D) Quantification of glucose levels using GC-TOF MS reveals that the Nrx-1 mutant
flies have reduced glucose levels relative to the iso31w- mutant flies. The box plot
depicts the autoscaled peak height of glucose on the y-axis. Mann-Whitney U test
revealed that both Nrx-1273/273 (P=0.021421) and Nrx-1241/241 (P=0.019413) flies have
decreased glucose levels compared to iso31Bw- flies. Six samples of 40 flies for each
genotype were used for the analysis. (E) Quantification of glycogen in 3- to 5-day-old
adult male flies. Each data point represents an independent sample of 4 fly bodies. Oneway ANOVA with Tukey’s multiple comparisons post-hoc test indicated that Nrx-1-null
mutant flies have decreased glycogen stores (P<0.0001) compared to wild-type
conspecifics. Sample number (N) per genotype: iso31Bw- N = 15, Nrx-1273/273 N = 15,
Nrx-1241/241 N = 14. (F) Average amount of food consumed by flies of each genotype
after an 18-hour overnight fasting period. Each data point represents an independent
sample of 5 whole flies. One-way ANOVA with Tukey’s multiple comparisons post-hoc
test showed that Nrx-1-null mutant flies eat the same amount of food as iso31Bwcontrol flies (P = 0.6406). Sample number (N) per genotype: iso31Bw- N = 14, Nrx50

1273/273 N = 14, Nrx-1241/241 N = 14. (G) Average activity during wake is shown for
individual flies of each genotype. Kruskal-Wallis test with Dunn’s multiple comparisons
test indicated that both Nrx-1273/273 flies (P= 0.0001) and Nrx-1241/241 flies (P<0.0001)
show decreased activity during wake compared to iso31Bw- control flies. Sample
number (N) per genotype: iso31Bw- N = 51, Nrx-1273/273 N = 52, Nrx-1241/241 N = 56. (H)
Average activity counts per 24-hour day are shown for individual flies of each genotype,
values shown are the average of 3 days of activity data combined. One-way ANOVA
with Tukey’s multiple comparisons post-hoc test revealed that Nrx-1273/273 mutant flies
show increased daily activity (P= 0.0003), whereas Nrx-1241/241 flies show no difference
in daily activity (P> 0.9999) compared to iso31Bw- control flies. Sample number (N) per
genotype: iso31Bw- N = 53, Nrx-1273/273 N = 53, Nrx-1241/241 N = 58. Values represent
mean ± SEM.
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Table 2.1. Significantly altered complex lipids in Nrx-1 mutants. 3- to 5-day-old adult
male flies of each genotype were analyzed for complex lipids by CSH-QTOF MS/MS. Six
samples of 40 flies for each genotype were used for the analysis. Table only includes
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known lipids that were significantly different (P<0.05) in both the Nrx-1273/273 and Nrx1241/241 groups when compared to iso31Bw- controls by a Mann-Whitney U test with false
discovery rate corrected P value. Fold change, calculated as FC= median (metabolite in
group 1)/median (metabolite in group 2), is listed for Nrx-1273/273 vs. iso31Bw-, and Nrx1241/241 vs. iso31Bw-. Boxes shaded in green indicate a significant decrease in lipid levels
in Nrx-1 mutants, and boxes shaded in red indicate a significant increase in lipid levels in
Nrx-1 mutants. A more detailed version of Table 1 can be viewed in the supplemental
material (Table S2.1).
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Figure 2.3. Nrx-1 mutants exhibit altered tryptophan, kynurenine, and NAD+ levels.
Quantification of (A) tryptophan and (B) kynurenine by GC-TOF MS in Nrx-1 mutants
and iso31Bw- controls. Six samples of 40 flies for each genotype were used for the
analysis. Box plots depict the autoscaled peak height of metabolites on the y-axis.
Mann-Whitney U test revealed that both Nrx-1273/273 (P=0.021421) and Nrx-1241/241
(P=0.019413) flies exhibit elevated tryptophan levels. Similarly for kynurenine, Nrx1273/273 (P=0.021421) and Nrx-1241/241 (P=0.019413) flies showed increased kynurenine
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levels compared to wildtype flies. Additionally, Mann-Whitney U test indicated no
significant difference in tryptophan or kynurenine levels between Nrx-1273/273 and Nrx1241/241 flies. Quantification of (C) NAD+, (D) NADH, and the (E) NAD+/NADH ratio in Nrx1 mutants and wildtype flies. The levels of NAD+ and NADH were normalized to protein
content. Each data point represents an independent sample of 10 fly bodies. One-way
ANOVA followed by Tukey-HSD post-hoc test indicated that compared to iso31Bwcontrols, NAD+ levels were significantly decreased in both Nrx-1273/273 (P<0.0001) and
Nrx-1241/241 (P=0.0001) flies. NADH levels were not significantly different than controls.
The NAD+/NADH ratio was significantly diminished in both Nrx-1273/273 and Nrx-1241/241
flies (P<0.0001). These experiments were performed 3 independent times. The NAD+
and NADH values shown (C and D) are representative figures from one experiment. The
NAD+/NADH ratio is internally normalized, allowing data to be pooled from all 3
independent experiments. Sample number (N) per genotype for NAD+ and NADH data =
3. Sample number (N) per genotype for NAD+/NADH ratio data: iso31Bw- N = 7, Nrx1273/273 N = 8, Nrx-1241/241 N = 8. Values represent mean ± SEM.
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Figure 2.4. Loss of Nrx-1 leads to abnormal mitochondrial morphology and
impaired flight. Longitudinal sections of indirect flight muscle of iso31Bw- flies (A and
D), Nrx-1273/273 flies (B and E), and Nrx-1241/241 flies (C and F) were prepared from
isolated thoraces for transmission electron microscopy experiments. (A-C) Electron
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micrographs of Drosophila flight muscle at 7,500X magnification. Scale bar indicates 2
microns. (D-F) Electron micrographs of Drosophila flight muscle at 20,000X
magnification. Scale bar indicates 800 nm. Images show mitochondria (M) aligned
between rows of myofibrils (F), where Nrx-1 mutants have irregularly spaced
mitochondria with marked disruptions in the cristae. Arrowheads denote disruptions in
cristae. Asterisks signify areas devoid of cristae. (G) Quantification of the average
landing height for flies of each genotype in a glycerol flight assay. Each data point
represents an individual fly. Kruskal-Wallis test with Dunn’s multiple comparisons posthoc test showed that Nrx-1273/273 and Nrx-1241/241 flies performed significantly worse on a
glycerol flight assay compared to control flies. Sample number (N) per genotype:
iso31Bw- N = 66, Nrx-1273/273 N = 67, Nrx-1241/241 N = 63. Values represent mean ± SEM.
**** = P<0.0001.
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Figure 2.5. Nrx-1 mutant flies exhibit seizure-like activity after mechanical
stimulation. (A) Quantification of the percentage of flies seizing per genotype. Flies
were collected into groups of 5 flies per vial prior to a 10-second mechanical shock. Chisquare test was used to compare the penetrance of seizures. Sample number (N) per
genotype: iso31Bw- N = 75, Nrx-1273/273 N = 75, Nrx-1241/241 N = 75. (B) Quantification of
the duration of seizure-like activity after mechanical shock for flies of each genotype.
Each data point represents an individual fly. Kruskal-Wallis test with Dunn’s multiple
comparisons post-hoc test showed that Nrx-1273/273 (P=0.0003) and Nrx-1241/241
(P<0.0001) flies show a significant increase in the time taken to regain their posture
following a mechanical shock. This quantification period was capped at a maximum of
60 seconds, and thus flies that continued seizure-like behavior beyond that period were
excluded from this analysis. Sample number (N) per genotype: iso31Bw- N = 75, Nrx-
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1273/273 N = 68, Nrx-1241/241 N = 62. Values represent mean ± SEM. ***= P<0.001, ****=
P<0.0001
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Supplementary Information

Figure S2.1. Nrx-1273/241 transheterozygotes exhibit the same behavioral and
metabolic alterations as seen in Nrx-1 homozygous mutant flies.
(A) Survival curve of Nrx-1273/241 transheterozygous mutants (purple) and wild-type
iso31Bw- controls (black) during starvation. Log-rank (Mantel-Cox) test results indicated
that Nrx-1273/241 flies die significantly faster than wild-type flies when on media containing
0% sucrose and 2% agar. Sample number (N) per genotype: iso31Bw- N = 67, Nrx60

1273/241 N = 67. (B) Quantification of triglycerides in 3- to 5-day-old adult male flies. Each
data point represents an independent sample of 3 fly bodies. Unpaired t-test indicated
that Nrx-1273/241 flies have significantly decreased triglycerides compared to iso31Bwcontrol flies. Sample number (N) per genotype: iso31Bw- N= 15, Nrx-1273/241 N = 15. (C)
Quantification of the average landing height for flies of each genotype in a glycerol flight
assay. Each data point represents an individual fly. Mann-Whitney test indicated that
Nrx-1273/241 flies have significantly decreased flight ability compared to control flies.
Sample number (N) per genotype: iso31Bw- N = 75, Nrx-1273/241 N = 76. (D)
Quantification of the percentage of flies seizing per genotype. Sample number (N) per
genotype: iso31Bw- N = 75, Nrx-1273/241 N = 75. Fisher’s exact test indicated that a
greater percentage of Nrx-1273/241 flies exhibit seizure-like behavior. (E) Quantification of
the duration of seizure-like activity after mechanical shock for flies of each genotype.
Mann-Whitney test showed that Nrx-1273/241 flies show a significant increase in the time
taken to regain their posture following a mechanical shock compared to controls. Sample
number (N) per genotype: iso31Bw- N = 75, Nrx-1273/241 N = 59. Values represent mean
± SEM. **** = P<0.0001.
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Table S2.1. Significantly altered complex lipids in Nrx-1 mutants (extended
version). 3- to 5-day-old adult male flies of each genotype were analyzed for complex
lipids by CSH-QTOF MS/MS. Six samples of 40 flies for each genotype were used for
the analysis. Table only includes known lipids that were significantly different in both the
Nrx-1273/273 and Nrx-1241/241 groups when compared to iso31Bw- controls by a MannWhitney U test with false discovery rate corrected P value. For each lipid, the p-value of
the Mann-Whitney U test is listed for Nrx-1273/273 vs. iso31Bw-, and Nrx-1241/241 vs.
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iso31Bw-. Fold change, calculated as FC= median (metabolite in group 1)/median
(metabolite in group 2), is listed for Nrx-1273/273 vs. iso31Bw-, and Nrx-1241/241 vs.
iso31Bw-. Boxes shaded in green indicate a significant decrease in lipid levels, and
boxes shaded in red indicate a significant increase in lipid levels.
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Table S2.2. Significantly altered primary metabolites in Nrx-1 mutants versus
control animals. 3- to 5-day-old adult male flies of each genotype were analyzed for
primary metabolites by GC-TOF MS. Six samples of 40 flies for each genotype were
used for the analysis. Table only includes known primary metabolites that were
significantly different in both the Nrx-1273/273 and Nrx-1241/241 groups when compared to
iso31Bw- controls by a Mann-Whitney U test with false discovery rate corrected p-value.
64

For each metabolite, the p-value of the Mann-Whitney U test is listed for Nrx-1273/273 vs.
iso31Bw-, and Nrx-1241/241 vs. iso31Bw-. Fold change, calculated as FC= median
(metabolite in group 1)/median (metabolite in group 2), is listed for Nrx-1273/273 vs.
iso31Bw-, and Nrx-1241/241 vs. iso31Bw-. The last column indicates the directionality of
the change in metabolite levels in Nrx-1 mutants, either an up arrow for an increase in
metabolite levels (orange) or a down arrow for a decrease in metabolite levels (green).
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Figure S2.2. Nrx-1 mutant flies have decreased, fragmented sleep during the night.
Sleep was measured in 3- to 5-day-old adult male flies using the Drosophila Activity
Monitoring (DAM) System. (A) Average total minutes of sleep during the night was
significantly decreased in Nrx-1 mutants, Kruskal-Wallis test with Dunn’s multiple
comparisons test. Sample number (N) per genotype: iso31Bw- N = 51, Nrx-1273/273 N =
52, Nrx-1241/241 N = 58. (B) The number of sleep bouts during the night was significantly
increased in both Nrx-1-null mutants, Kruskal-Wallis test with Dunn’s multiple
comparisons test. Sample number (N) per genotype: iso31Bw- N = 53, Nrx-1273/273 N =
52, Nrx-1241/241 N = 55. (C) Sleep bout length during the night was significantly
decreased in Nrx-1 mutant flies, Kruskal-Wallis test with Dunn’s multiple comparisons
test. Sample number (N) per genotype: iso31Bw- N = 48, Nrx-1273/273 N = 52, Nrx-1241/241
N = 56. Values represent mean ± SEM. ****P<0.0001.
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Figure S2.3. Loss of Nrx-1 does not affect body weight. One-way ANOVA followed
by Tukey-HSD post-hoc test indicated that Nrx-1273/273 (P=0.9980) and Nrx-1241/241
(P=0.7930) mutant flies show no difference in weight compared to wildtype flies. Four
samples of 10-20 flies for each genotype were used for the analysis. Values represent
mean ± SEM.
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Figure S2.4. Schematic representation of NAD synthesis pathways in Drosophila
melanogaster. Enzymes are depicted in blue. Abbreviations— D-TDO2, Drosophila
tryptophan 2,3-dioxygenase; NAM, nicotinamide; D-NAAM, Drosophila nicotinamidase;
NA, nicotinic acid; D-NAPRTase, Drosophila nicotinic acid phosphoribosyltransferase;
NAMN, nicotinic acid mononucleotide; NAAD, nicotinic acid adenine dinucleotide; NADS,
NAD synthetase; NAD, nicotinamide adenine dinucleotide.
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Table S2.3. Metabolites within NAD synthesis pathways in Nrx-1 mutants
compared to control flies. 3- to 5-day-old adult male flies of each genotype were
analyzed for primary metabolites by GC-TOF MS. Six samples of 40 flies for each
genotype were used for the analysis. Table includes the metabolites within NAD
synthesis pathways that were included in the metabolomics screen. P values were
calculated using a Mann-Whitney U test with false discovery rate correction. For each
metabolite, the P value of the Mann-Whitney U test is listed for Nrx-1273/273 vs. iso31Bw-,
and Nrx-1241/241 vs. iso31Bw-. Fold change, calculated as FC= median (metabolite in
group 1)/median (metabolite in group 2), is listed for Nrx-1273/273 vs. iso31Bw-, and Nrx1241/241 vs. iso31Bw-. Fold change boxes shaded in red indicate a significant increase in
metabolite levels, and unshaded boxes indicate no significant change in metabolite level
compared to controls.
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Figure S2.5. Treatment with nicotinamide riboside (NR) during adulthood does not
improve starvation resistance in Nrx-1 mutant Drosophila. (A) Starvation resistance
curve for iso31Bw-, Nrx-1273/273, and Nrx-1241/241 flies treated with either vehicle or NR. (BD) Starvation curves for each genotype from (A) are shown separately for ease of
viewing. Both Nrx-1-null flies and iso31Bw- flies were raised on normal fly food, and they
were subsequently collected into vials with fly food containing 500 μM NR from day 0-1
post-eclosion until the flies were 3-to-5-days old. The flies were then placed into
circadian tubes containing 0% sucrose agar for the starvation experiment. Log-rank
Mantel Cox test revealed no significant difference between vehicle treated vs. 500 μM
NR treated flies for each genotype. Sample number (N) per group: iso31Bw- Vehicle =
18, iso31Bw- NR = 18, Nrx-1273/273 Vehicle = 11, Nrx-1273/273 NR = 17, Nrx-1241/241 Vehicle
= 6; Nrx-1241/241 NR = 7. Values represent percentage ± SE.
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Figure S2.6. Treatment with nicotinamide (NAM) during development and
adulthood does not improve starvation resistance in Nrx-1 mutant Drosophila. (A)
Starvation resistance curve for iso31Bw-, Nrx-1273/273, and Nrx-1241/241 flies treated with
either vehicle or NAM. (B-D) Starvation curves for each genotype from (A) are shown
separately for ease of viewing. Nrx-1-null and iso31Bw- flies were raised on food that
contained 30mg NAM/100g food, and they were subsequently placed into vials
containing 30mg NAM/100g food from day 0-1 post-eclosion until the flies were 3-to-5days old. The flies were then placed into circadian tubes containing 0% sucrose agar for
the starvation experiment. Log-rank Mantel Cox test revealed no significant difference
between vehicle-treated vs. NAM-treated iso31Bw- flies or Nrx-1241/241 flies. In panel C,
Nrx-1273/273 flies treated with NAM actually showed decreased starvation resistance
compared to vehicle-treated Nrx-1273/273 flies (P =0.0202). Sample number (N) per group:
iso31Bw- Vehicle = 29, iso31Bw- NAM = 31, Nrx-1273/273 Vehicle = 28, Nrx-1273/273 NAM =
28, Nrx-1241/241 Vehicle = 15; Nrx-1241/241 NAM = 20. Values represent percentage ± SE.
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Materials and Methods

Fly genetics and husbandry
Fly strains that contain the Nrx-1273 and Nrx-1241 alleles are described in Li et al., (109).
These flies were outcrossed in the w1118(iso31Bw-) background for 6 generations and
maintained over a third chromosome balancer to avoid recombination events. The fly
strains were cultured on a standard cornmeal molasses medium and maintained in the
presence of 12h light: 12h dark (LD) cycle at 25°C.

Starvation stress
Male flies were collected 0-1 days post eclosion and entrained to a stringent 12h light:
12h dark cycle for 3-4 days at 25°C. Flies were then placed in individual glass tubes
containing 0% sucrose, 2% agar, and loaded into activity monitors (Trikinetics, DAM2
system, Waltham, MA) that were then returned to a 12h light: 12h dark light cycle at
25°C. The experiment was concluded when all flies were confirmed dead. Time of death
after the onset of starvation was determined by the final activity count recorded by the
activity monitors.

Heat stress
The heat stress protocol was modified from Folk et al., (156). 3- to 5-day-old adult male
flies were placed in groups of 10 into empty plastic vials without CO2. The empty vials
were then submerged in a 37°C water bath for 1 hour. After heat exposure, flies were
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flipped to new plastic vials containing standard cornmeal molasses medium and then
returned to 25°C. After 24 hours, the number of dead flies per vial was recorded.

Metabolomics
3- to 5-day-old adult male flies were collected on dry ice at approximately ZT0-ZT1. Flies
of each genotype were then pooled into 6 independent groups comprised of 40 whole
flies each. These samples were then sent for metabolomics analysis of primary
metabolites

and

complex

lipids

at

the

West

Coast

Metabolomics

Center

(https://metabolomics.ucdavis.edu/). Primary metabolites were probed using ALEX-CIS
GCTOF MS and complex lipids were analyzed using CSH-ESI QTOF MS/MS. A more
detailed description of the data acquisition procedures and chromatographic parameters
can be found in Fiehn O. et al., (203) and Matyash V. et al., (204).

Triglyceride measurement
Measurement of triglycerides was performed as described in Weisz et al., (72). Briefly,
3- to 5-day-old adult male flies were collected on dry ice at approximately ZT0-ZT1.
Samples for triglyceride measurement contained 3 flies each, and fly heads were
removed prior to homogenization. Fly bodies were homogenized in lysis buffer that
contained 140mM NaCl, 50mM Tris-HCl (pH 7.4), 20% Triton X-100, and 1X protease
inhibitors (Roche, Indianapolis, IN). The homogenate was then centrifuged at 15871 x g
for 10 minutes at 4°C. Triglyceride concentration for each sample was determined in
triplicate using the Triglyceride LiquiColor kit (Stanbio Laboratory, Boerne, TX), and was
normalized to protein content using the Pierce BCA Protein Assay Kit (Thermo Scientific,
Rockford, IL).
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Glycogen measurement
Measurement of glycogen was performed as described in Weisz et al., (72). Briefly, 3- to
5-day-old adult male flies were collected on dry ice at approximately ZT0-ZT1. Samples
each had 4 decapitated fly bodies, which were homogenized in 200µL of 0.1M NaOH.
The homogenate was centrifuged at 15871 x g for 10 minutes at 4°C. The supernatant
was extracted from each sample and 20 µL of the lysate was treated with 5 mg/mL
Amyloglucosidase (Sigma- Aldrich, Saint Louis, MO) in 0.2 M acetate, pH 4.8, as this
enzyme catabolizes glycogen to yield free glucose molecules. Concurrently, another 20
µL aliquot of the lysate was treated with 0.2 M acetate, pH 4.8 alone. Both reactions
incubated for 2h at 37°C. Subsequently, the free glucose content in each reaction was
measured in triplicate with the Amplex Red Glucose/ Glucose Oxidase Assay kit
(Molecular Probes, Eugene, OR). The glycogen concentration of each sample was
determined by subtracting the values of free glucose in the untreated samples. The
protein concentration of these reactions was then determined with the Pierce BCA
Protein Assay Kit (Thermo Scientific, Rockford, IL) for normalization.

Feeding
This feeding assay was modified from Edgecomb et al., (205). Briefly, 3- to 5-day-old
adult male flies of each genotype were fasted for an 18-hour period in plastic vials with
0% sucrose, 2% agar medium. After the fasting period, flies were flipped onto standard
cornmeal molasses medium containing 2.5mg/mL Brilliant Blue FCF (Sigma Aldrich).
After 1 hour of feeding, flies were anesthetized using CO2 and sorted into groups of 5
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flies each into 1.5mL Safelock Eppendorf tubes. The tubes were placed onto dry ice for
10 minutes, transferred onto wet ice, and then 130µL of chilled PBST was added to each
tube. Samples were homogenized and centrifuged at max speed for 15 minutes at 4°C.
After centrifuging, 50µL of supernatant for each sample was loaded into duplicate wells
on a 96-well plate and absorbance was measured at 620nm. The concentration of
Brilliant Blue FCF consumed in each sample was determined using a standard curve.

Activity/Sleep levels
Male flies of the appropriate genotype were collected 0–1 days post eclosion and
entrained to a stringent 12h light: 12h dark cycle for 3-4 days at 25°C. Flies were then
placed in individual tubes containing 5% sucrose, 2% agar, and loaded into monitors
(Trikinetics, DAM2 system, Waltham, MA) that were returned to a 12h light: 12h dark
cycle at 25°C. The activity of these flies, as indicated by beam breaks, was measured
from days 2 to 4. The daily activity of each fly was averaged over the 3 days used for
analysis, and the average daily activity of each genotype was determined. Sleep was
also measured during this 3-day period; sleep was defined as a period of 5 minutes of
inactivity. Flies that died at any time during the assay were excluded from analysis.

Weight measurement
1.5mL microcentrifuge tubes were first pre-weighed on a Mettler AE 100 Analytical
Balance. Then, 3- to 5-day-old adult male flies of the appropriate genotype were placed
into the tubes in groups of 10-20. Each sample was then weighed, and the weight/fly
was calculated.
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NAD+/NADH Quantification
Measurement of NAD+/NADH was performed as described in Weisz et al., (72). The
concentrations of nicotinamide nucleotides were measured using the NAD+/NADH
Quantification Colorimetric Kit (BioVision, Milpitas, CA). Briefly, adult male flies aged 3 to
5 days were collected on dry ice. Fly heads were removed prior to homogenization and
the decapitated fly bodies were pooled in groups of 10. The samples were homogenized
for 30 pulses in 400µl of the NAD+/NADH Extraction Buffer supplied in the kit, and the
homogenate was centrifuged at top speed for 5 minutes at 4°C to remove debris. The
cycling reaction was carried out as per the manufacturer’s instructions for 2 hours and
the nicotinamide nucleotide concentrations of each standard and sample were
determined in duplicate. The protein concentration of each sample was measured with
the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL) and the nicotinamide
nucleotide concentration of each sample was then normalized to its respective protein
content.

NAD+ precursor food preparation
Standard cornmeal molasses fly food was melted down to a liquid and subsequently
cooled to 60°C. Nicotinamide riboside (NR) was obtained from Sigma (SMB00907) and
added to the medium at a final concentration of 500µM. Nicotinamide (NAM) was
obtained from Sigma (481907) and was added to the medium at a final concentration of
30mg NAM/100g medium. Both NR and NAM were solubilized in water prior to adding
them to the medium. A commensurate amount of water without NR or NAM was added
to a separate batch of medium as a vehicle control medium.
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Transmission electron microscopy
Tissues for electron microscopic examination were fixed with 2.5% glutaraldehyde, 2.0%
paraformaldehyde in 0.1M sodium cacodylate buffer, pH7.4, overnight at 4°C. After
subsequent buffer washes, the samples were post-fixed in 2.0% osmium tetroxide for 1
hour at room temperature, and then washed again in buffer followed by dH2O. After
dehydration through a graded ethanol series, the tissue was infiltrated and embedded in
EMbed-812 (Electron Microscopy Sciences, Fort Washington, PA). Thin sections were
stained with lead citrate and examined with a JEOL 1010 electron microscope fitted with
a Hamamatsu digital camera and AMT Advantage image capture software.

Glycerol Flight Assay
The flight assay was modified from Elkins et al., (206). The inside of a 1000mL glass
graduated cylinder was coated with a thin layer of glycerol, and a group of 5-10 adult
male flies of the appropriate genotype was quickly flipped into the cylinder using a
funnel. Immediately after flipping the flies into the cylinder, a dry erase marker was used
to indicate where each fly landed within the cylinder. The landing height was recorded as
the corresponding measurement in mL on the cylinder. The glycerol was then rinsed out
and renewed for each group of flies.

Seizure Assay
Male flies of each genotype were collected 0–1 days post eclosion and entrained to a
stringent 12h light: 12h dark cycle for 3-4 days at 25°C. Flies of each genotype were
placed into empty plastic vials without CO2 in groups of 5 flies per vial. To induce
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seizure-like activity, the vials were vortexed at maximum speed for 10 seconds (182).
The flies were video recorded for quantification of the number of flies seizing per vial and
the time taken to regain their posture following the mechanical shock. Analysis of the
time to recovery was capped at a maximum of 60 seconds. Genotypes were blinded to
the scorer during the analysis.

Statistics
For the metabolomics data, univariate between-groups comparisons were conducted by
Christopher Brydges at the West Coast Metabolomics Center. Mann-Whitney U tests
(non-parametric) were conducted, and uncorrected and false discovery rate corrected P
values were calculated. Bayes factors were calculated for the same comparisons using a
Bayesian Mann-Whitney U, using a default prior distribution (207). The PCA plots are
the biplots of the first two components extracted from a principal components analysis,
with normal data ellipses for each group. For all other experiments, the Prism software
package (GraphPad Software, v9.2.0) was used to generate graphs and perform
statistical analyses. Parametric data was analyzed using either t-tests or one-way
analysis of variance (ANOVA) with post hoc Tukey tests, as appropriate. Non-parametric
data was analyzed using Mann-Whitney tests or Kruskal-Wallis tests with post hoc
Dunn’s tests, as appropriate. Chi-square test or Fisher’s exact test were used to
compare penetrance of seizure-like behavior. The log-rank (Mantel-Cox) test with a
Bonferroni-corrected significance threshold for multiple comparisons was used to
examine differences in stress resistance between genotypes.
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CHAPTER 3: FUTURE DIRECTIONS AND CONCLUDING REMARKS

Introduction
Metabolic dysfunction is becoming more well-known in the field as a co-occurring
condition in autism, as metabolic perturbations have been reported in autistic individuals
in numerous clinical studies. Given that NRXN1 is a significant risk gene for autism, I
hypothesized that disruptions in neurexin-1 lead to metabolic dysfunction. For my thesis
project, I utilized the powerful and genetically tractable Drosophila model system to
investigate perturbations in energy homeostasis, mitochondrial function, and seizure
susceptibility as a result of loss of the NRXN1 homologue, Nrx-1. To date, a majority of
the studies investigating Nrx-1 function in Drosophila have understandably focused their
efforts at the synapse and neuromuscular junction, and thus there is a lack of
understanding of systemic alterations that result from disruption of the Nrx-1 gene. To
begin to fill this gap in knowledge, I utilized metabolomic, physiological, and behavioral
methods to uncover novel roles of Nrx-1.
In Chapter 2, I demonstrated that Nrx-1-null Drosophila exhibit increased
sensitivity to starvation and heat stress, as well as a distinct metabolic profile
characterized by decreased lipid and carbohydrate energy stores. These deficits could
not be fully explained by differences in food intake or activity levels, and thus I next
probed mitochondrial functioning and morphology. These experiments revealed
alterations in metabolites involved in de novo NAD+ synthesis, as well as decreased
NAD+ levels and a diminished NAD+/NADH ratio. Upon investigation of mitochondrial
morphology, I uncovered that flight muscle mitochondria of Nrx-1-null Drosophila
showed severe disruptions in the cristae. Finally, Nrx-1 mutant flies exhibited
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significantly increased susceptibility to mechanical insults, showing seizure-like behavior
that is reminiscent of the clinical literature wherein NRXN1 patients experience seizures.
These findings are exciting as they point to a novel role for Nrx-1 as a regulator of
energy metabolism in Drosophila, and they serve as a foundation upon which future
studies may further investigate how Nrx-1 may stand at the intersection of metabolism,
mitochondrial function, and autism pathophysiology.
While these findings reveal novel systemic disruptions due to loss of Nrx-1, they
leave us with many remaining questions as well. The mechanism by which Nrx-1
regulates energy homeostasis and mitochondrial function, in addition to how these
alterations may contribute to autism-related behavioral phenotypes, is still yet to be
elucidated. In this Chapter, I will discuss possible routes of investigation to further inquire
the mechanisms by which Nrx-1 may function as a regulator of energy metabolism in
Drosophila, as well as my overall conclusions.

Future Directions
Determine the spatial requirements for Nrx-1 expression
Drosophila melanogaster are a powerful model system for further interrogation of
how Nrx-1 regulates energy metabolism not only due to the simplicity of Nrx-1, with only
one isoform and no alternative splicing, but also due to the availability of genetic tools
allowing for cell type- and tissue-specific re-expression or knockdown of Nrx-1. In
Drosophila, the binary UAS/GAL4 system is a powerful tool for spatial mapping studies.
The UAS/GAL4 consists of two components: the yeast transcriptional activator GAL4,
and the upstream activating sequence (UAS) to which GAL4 specifically binds to
activate gene transcription. GAL4 expression is controlled by a specific endo- or
81

exogenous promoter that directs spatially restricted GAL4 expression, and thus mating
flies that express tissue-specific GAL4 to transgenic flies with the UAS next to a gene of
interest, such as Nrx-1, results in expression of the gene of interest in a tissue or cell
type-specific manner (208). The UAS/GAL4 system can also be utilized for tissuespecific RNAi-mediated knockdown of gene expression by inserting the UAS upstream
of a gene fragment that is dimerized to produce a double-stranded RNA (dsRNA) hairpin
structure, which triggers sequence-specific post-transcriptional silencing, resulting in
targeted knockdown of the gene of interest (209,210).
Mapping studies in Drosophila performed with the UAS/GAL4 system have
identified neuronal populations in which Nrx-1 regulates behaviors such as locomotor
activity, associative learning, and sleep (108,109,140,141). Likewise, a genetic screen
could potentially uncover tissues and/or cells in which Nrx-1 is required or sufficient for
maintenance of metabolic homeostasis. We have performed preliminary mapping
experiments for these hypotheses using a UAS-Nrx-1 rescue construct and UAS-Nrx-1RNAi constructs, although there were technical complications with the use of these
genetic reagents that impeded these experiments (see Appendix D). The Jongens lab
has since obtained new UAS constructs to revisit these experiments in the future.
Nonetheless, given that there is crosstalk between the central nervous system
and the periphery that informs cellular decisions to either store or mobilize nutrients
(166,211), Nrx-1 could potentially act in neuronal and/or peripheral tissues to regulate
nutrient homeostasis. In adult Drosophila, Nrx-1 is expressed broadly throughout the
central nervous system, as well as in motor neurons, muscle, gut, salivary glands, wings,
and legs (137,138). It would be highly informative to assess whether Nrx-1 is required or
sufficient for metabolic regulation in the central nervous system using the elav-GAL4
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pan-neuronal driver. If so, it would be interesting to screen additional GAL4 drivers that
are specific to different subsets of cells in the CNS to identify a precise circuit in which
Nrx-1 regulates the observed metabolic, mitochondrial, and/or behavioral phenotypes.
Of particular interest for these experiments would be the insulin producing cells (IPCs),
which are located within the pars intercerebralis (PI) region of the brain and are highly
involved in the regulation of energy metabolism (184–188). In vertebrates, NRXN1α
regulates insulin granule docking and insulin secretion via actions in the insulinproducing pancreatic β-cells (148,149). Additionally, our lab previously showed elevated
insulin signaling in a Drosophila model of Fragile X Syndrome (73), which also exhibits
striking similarities to the Nrx-1 mutants in several of the metabolic defects described in
Chapter 2 (72). Therefore, misregulation of the release of Drosophila insulin-like
peptides may lead to the observed metabolic alterations in the Nrx-1 flies.
Another neuronal subpopulation of interest would be the octopamine neurons.
Octopamine is the invertebrate equivalent of norepinephrine, and it has been shown to
have a crucial role in the regulation of starvation resistance and lipid metabolism in
Drosophila (212,213). Interestingly, octopamine was previously shown to interact with
the insulin signaling pathway in the regulation of metabolism (212). It is possible that
loss of Nrx-1 disrupts octopamine signaling interactions with the IPCs, resulting in
altered energy metabolism. It would be highly informative to see if knockdown or reexpression of Nrx-1 in the octopamine neurons either recapitulates or rescues the
metabolic and behavioral phenotypes seen in the Nrx-1-null mutants.
Additionally, these mapping studies should also extend to peripheral tissues,
particularly the muscle and the gut, in which Nrx-1 is also expressed. Muscle plays a
central role in the control of energy homeostasis via the consumption of energy, as well
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as through endocrine signaling between muscle and other tissues, such as adipose
tissue (214,215). Nrx-1 has been shown to be expressed pre- and post-synaptically in
the Drosophila neuromuscular junction (NMJ) (137,138), and Hu et al. (2012)
demonstrated that Nrx-1 and neuroligin (Nlg-1) in C. elegans mediate a retrograde
synaptic signal that inhibits neurotransmitter release at the NMJ (216). Thus, it could be
hypothesized that in the absence of Nrx-1, synaptic release kinetics at the NMJ could be
altered, resulting in changes in muscle-dependent regulation of energy metabolism. As
mentioned before, the gut would be another tissue of interest for these mapping studies,
as the gut plays a large role in modulating organismal metabolic homeostasis as well as
behavior through coordination of intestinal, neuronal, and adipose tissue-signaling
networks (217,218).

Define potential genetic interactions with Nrx-1
As mentioned in Chapter 1, autism is a highly heterogenous condition with more
than 100 genes that have been identified as significant autism risk genes (83–85).
Moreover, in complex diseases such as autism and schizophrenia, genetic interactions
and epistasis can result in variable penetrance of genetic mutations, where an allele can
result in a clinically significant phenotype in one genetic background but not in another
genetic background. For instance, both intronic and exonic deletions in NRXN1 can be
found in autistic individuals as well as in their unaffected parents or siblings, highlighting
the variable penetrance of NRXN1 deletions (122,125). In these cases, it is thought that
these NRXN1 deletions require a “second hit,” which is a secondary, independent
pathogenic mutation in another autism risk gene to synergistically disrupt
neurodevelopment and reach threshold for a clinical diagnosis (122). To this end, it
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would be of high interest to better understand how multilocus allelic combinations
contribute to metabolic dysfunction in autism, which could highlight potential functional
links between neurexin-1 and other genes in the regulation of energy homeostasis.
Additionally, genetic interaction studies would help to identify a potential pathway or
mechanism by which Nrx-1 plays a role in regulating metabolism.
Drosophila are an ideal model system for genetic interaction screens, due to the
wide availability of mutant alleles and RNAi constructs for many genes of interest. A
screen for the identification of genetic interaction partners with Nrx-1 in the regulation of
energy metabolism should prioritize autism risk genes that are known to bind directly
with neurexin-1. Additionally, autism risk genes in general, especially those that act at
the synapse, should also be prioritized as they may interact indirectly with Nrx-1 through
a network of interacting gene products. For example, Neuroligins (Nlgs), Shank, GABA
receptors, and CASK would all be genes of high interest for these experiments.
Additionally, this genetic interaction screen could also extend to genes known to regulate
mitochondrial functioning and biogenesis, such as PCG1α.
Ideally, this screen would begin with null mutants, or ubiquitous or pan-neuronal
knockdown, of each single orthologous gene in Drosophila, with subsequent behavioral
or physiological assays, such as starvation resistance, seizures, and triglyceride and
glycogen measurements. These assays would be relatively high-throughput, allowing for
a more comprehensive screen of an array of genes that may also regulate energy
homeostasis. If these experiments were to identify a gene that influences energy
metabolism or related behaviors, the next step would be to assess whether disruption of
both Nrx-1 and the gene of interest results in a modified phenotype. For example, if
Neuroligin-null Drosophila were found to mimic the metabolic or behavioral phenotypes
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seen in the Nrx-1 mutants, it would be informative to then assess the phenotype of a
Nrx-1;Nlg double mutant. If Nrx-1 and Nlg were to participate in the same pathway in the
regulation of energy metabolism, then the magnitude of the resultant deficit in the double
mutant should be comparable to that of each single mutant. Conversely, if Nrx-1 and Nlg
were to function in separate pathways, then there would be an additive effect wherein
the magnitude of the resultant deficit will be greater in the Nrx-1;Nlg double mutant
compared to either single mutant. Additionally, there could be an antagonistic effect
where the double mutant phenotype is milder than the more severe of the single
mutants. These epistasis experiments could help to identify a functional link between
Nrx-1 and other autism risk genes in the regulation of energy metabolism, as well as
uncover possible mechanisms for how Nrx-1 could modulate transsynaptic interactions
or second messenger signaling pathways that may subsequently affect mitochondrial
functioning and energy homeostasis.
Our lab previously reported similar deficits in starvation resistance, decreased
energy stores, diminished NAD+, and mitochondrial fragmentation in a Drosophila model
of Fragile X Syndrome, in which the Fmr1 gene is disrupted (72). Given the striking
similarities in metabolic phenotypes between the Nrx-1-null mutants and the Fmr1-null
mutants, it would be exciting to assess for a potential genetic interaction between these
genes. In mice, it has actually been shown that Nrxn1 is a target gene for the Fragile X
mental retardation protein (FMRP), which is a polyribosome-associated neuronal RNAbinding protein (219). To this end, FMRP may repress translation of Nrxn1 mRNA
transcripts. Epistasis experiments investigating an interaction between Nrx-1 and Fmr1
in the regulation of energy metabolism could illuminate converging mechanisms for
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metabolic control among autism risk genes, as well as elucidate the etiology of metabolic
dysfunction in autism and neuropsychiatric disorders.

Establish how metabolic dysfunction contributes to autism-related phenotypes in
Nrx-1 mutant Drosophila
Co-occurring conditions are common in autism, with almost 70% of autistic
individuals experiencing at least one co-occurring disorder, and nearly 40% experiencing
two or more psychiatric disorders (37). Autistic children with co-occurring mitochondrial
dysfunction also show an increased prevalence of developmental regression, seizures,
motor delays, and gastrointestinal abnormalities (i.e. reflux or constipation) (18).
Importantly, these co-occurring conditions have the potential to interact with and
exacerbate each other. For example, autistic children with poor sleep quality also show
lower performance on social cognition and social communication skills compared to
autistic children without sleep disturbances (38). Considering the critical importance of
the mitochondria in producing cellular energy, mitochondrial and metabolic disturbances
could very well contribute to dysfunction in tissues with high energy demands, like the
brain, potentially leading to widespread synaptic dysfunction. To this end, there is a
growing hypothesis in the field that metabolic disturbances may contribute to various
cognitive and behavioral alterations in autism (50,55,65,191,220).
Previous studies have shown that certain metabolic therapies, mainly dietary
interventions, may help to improve cognition, anxiety, and seizures in autistic individuals
(50,220). For example, one study reported improvements on the Childhood Autism
Rating Scale on concentration and learning abilities, as well as social behavior and
interactions, in autistic children given an intermittent ketogenic diet (221). Additionally, a
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case study in a child with autism and epilepsy showed decreased seizure frequencies,
as well as improvements on the Childhood Autism Rating Scale after treatment with a
ketogenic, gluten-free, casein-free diet (222). It is important to note that clinical studies
assessing effects of dietary interventions in autism are limited, and often show mixed
results, thus further research is necessary here. Additionally, studies in animal models of
autism have also shown improvements after metabolic therapy. In one example, Mecp2
mutant mice showed improved motor behavior and reduced anxiety after treatment with
a ketogenic diet compared to animals given a standard diet (223). Taken together, there
is some evidence to suggest that mitochondrial and metabolic dysfunction may be a
contributor to certain co-occurring conditions seen in autism. However, with respect to
the findings presented in Chapter 2, the extent to which the metabolic deficits in the Nrx1 mutants underlie the observed alterations in stress resistance and seizure-like activity
is yet to be fully explored.
Our lab has performed preliminary experiments to assess whether specific
pharmacological or dietary interventions aimed at improving metabolism and
mitochondrial functioning can positively impact starvation stress resistance in the Nrx-1null flies (Appendix C). Briefly, we were unable to rescue starvation resistance back to
wildtype levels with treatment with NAD+ precursors, Rolipram (a phosphodiesterase-4
inhibitor), or a high sucrose diet. It is possible that these experiments were unsuccessful
due to insufficient dosage or incorrect timing of drug delivery, and thus there is still a
possibility that these interventions could improve stress resistance in the Nrx-1 mutants.
Additional dietary manipulations, including increased sucrose and fats, may help to
boost the diminished glycogen and triglyceride levels seen in the Nrx-1 mutants, and
subsequently improve stress resistance or seizure-like activity. Additionally, our lab
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previously showed that adulthood administration of metformin, a widely-used drug for
type 2 diabetes, rescues short-term and long-term memory in Fmr1 mutant flies (73).
Metformin is a modulator of mitochondrial functioning, and although its mechanism of
action is not completely understood, it is known to act as an insulin signaling sensitizer.
Given the similarities in metabolic and mitochondrial phenotypes seen between the Nrx1 mutants and the Fmr1 mutants, the two models may also exhibit similarities in
misregulation of insulin signaling. If so, it would be interesting to probe whether
metformin treatment is able to rescue the metabolic and behavioral phenotypes seen in
the Nrx-1 mutants.
By utilizing metabolic interventions, such as pharmacological agents, special
diets, or dietary supplementation, we could attempt to improve the metabolic status of
Nrx-1 mutant flies and then subsequently assess for improvements in autism-related
behavioral phenotypes. These studies could elucidate how metabolic and mitochondrial
dysfunction contribute to disorders commonly seen in autism, such as seizures and
impaired stress resistance, which could then lead to the improvement of therapeutic
options for autistic individuals with metabolic dysfunction and additional co-occurring
conditions.

Measure insulin signaling in Nrx-1 mutants
Our lab previously identified alterations in energy metabolism and mitochondrial
function in Drosophila lacking the Fmr1 gene, a Drosophila model for Fragile X
Syndrome. Specifically, the Fmr1 mutant flies showed decreased triglyceride and
glycogen stores, increased sensitivity to starvation stress, decreased NAD+ levels and a
diminished NAD+/NADH ratio, as well as disrupted mitochondrial morphology (72). The
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findings I presented in Chapter 2 in the Nrx-1 mutants closely mimic the perturbations
seen in the Fmr1 mutant flies, and thus it is possible that the underlying cause of altered
energy homeostasis and mitochondrial functioning may be shared between both models.
Our lab also showed previously that insulin signaling is elevated in the brains of Fmr1
mutants (73). While my thesis serves as a foundation in characterizing metabolic and
mitochondrial alterations due to loss of Nrx-1, we still have remaining unanswered
questions as to how Nrx-1 may regulate metabolism in Drosophila. Given the striking
similarities between the Nrx-1 mutants and Fmr1 mutants, it would be exciting to
determine whether Nrx-1 mutants also have misregulated insulin signaling as was seen
in the Fmr1 mutants. In mammals, NRXN1α is expressed in the pancreatic the insulinproducing pancreatic β-cells where it regulates insulin secretion (148,149). It is possible
that Nrx-1 has a similar role in the insulin producing cells (IPCs) in Drosophila, which are
located within the pars intercerebralis (PI) region of the brain. To pursue the hypothesis
that Nrx-1 plays a role in energy homeostasis in Drosophila via the regulation of insulin
signaling, it would be necessary to measure components of the insulin signaling
pathway.
In the Drosophila insulin signaling pathway, Drosophia insulin-like peptides
(dilps) activate the insulin receptor (InR), which results in InR auto-phosphorylation and
subsequent phosphorylation of phosphoinositide 3-kinase (PI3K). Once activated, PI3K
converts phospholipid phosphatidylinositol (4,5)-biphosphate (PIP2) into
phosphatidylinositol (2,4,5)-triphosphate (PIP3). This PI3K-driven increase in PIP3
recruits Akt to the membrane, where is it subsequently phosphorylated and activated
(224). Akt has several downstream phosphorylation targets itself, which perform various
actions that impact lipid and carbohydrate biosynthesis and breakdown (224). To
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measure components of the insulin signaling pathway in Nrx-1-null mutants,
immunofluorescence measurements of dilps in the IPCs should be performed, in
addition to measurement of dilp mRNA transcript levels using quantitative RT-PCR. In
the Fmr1 mutant flies, our lab identified significantly elevated dilp2 protein levels in the
IPCs, suggesting elevated insulin signaling results from loss of Fmr1 (73). Our lab has
also previously measured PI3K activity levels using a GFP-pleckstrin homology (PH)
reporter protein, which localizes to the plasma membrane when membrane PIP3 levels
increase upon activation of PI3K when the insulin pathway is stimulated. PI3K activity
can then be measured using immunofluorescence to quantify GFP-PH localization at the
membrane. Another measurement to assess for insulin signaling misregulation is to
measure phosphorylated Akt levels using whole-mount immunostaining and confocal
analysis. Elevated PI3K activity as well as increased phosphorylated Akt were also
reported in the Fmr1 mutants (73). Performing similar experiments in the Nrx-1 mutants
would help to uncover whether insulin signaling is misregulated in the absence of Nrx-1,
as it is in Fmr1-null flies. These studies could then point to a potential mechanism for
Nrx-1-dependent regulation of energy homeostasis, opening up possibilities for future
therapeutics for autistic individuals with metabolic disorders.

Assess energy metabolism in the brain of Nrx-1-null mutants
The findings I presented in Chapter 2 demonstrated striking alterations in energy
metabolism and mitochondrial morphology in peripheral tissues in Nrx-1 mutant flies.
Given that neurexin-1 is a synaptic cell adhesion molecule that is primarily expressed in
the CNS, the consequences of loss of neurexin-1 in the periphery have largely been
ignored in the field. I initially elected to investigate stress resistance in the Nrx-1 mutant
91

flies as it relates to increased anxiety and stress in autism, though upon the discovery
that Nrx-1 mutants are more sensitive to nutrient deprivation stress and heat stress I was
inspired to assess alterations in peripheral metabolism in these flies. These experiments
were further inspired by findings in the field showing alterations in peripheral markers of
metabolic and mitochondrial dysfunction in the autism patient population, including those
found in blood and urine (18,21,23,57–59).
In the future, it would be informative to assess whether energy metabolism is
also disrupted in the brain in Nrx-1-null flies by repeating the experimental approaches
that I discussed in Chapter 2 using brain tissue. Nrx-1 is expressed broadly throughout
the CNS in Drosophila (138), as well as in the muscle and gut which also have important
influences on metabolism. As there is important cross-talk between the CNS and the
periphery in the regulation of organismal metabolism (166,211), it is possible that Nrx-1
could act cell-autonomously or cell-non-autonomously to influence energy metabolism in
the brain. Investigating brain metabolism in Nrx-1 mutants would also be interesting from
a behavioral and cognitive standpoint, as proper CNS function relies on the availability of
energy stores and mitochondrial functioning to general maximal quantities of ATP. For
example, if energy metabolism were also disrupted in the brain of Nrx-1-null flies, this
could further inform the seizure-like behavior phenotype seen in these flies. Seizures
have been hypothesized to be a result of an imbalance of excitatory and inhibitory
signaling in the brain, and GABAergic interneurons have an especially high firing rate
and high energy needs (14,46). Thus, disruption of energy metabolism and
mitochondrial functioning in the brain of Nrx-1 mutants could result in decreased
inhibitory neurotransmission and an increased E/I ratio, which could be contributing
factor underlying the seizure-like behavior phenotype in these flies.
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Determine whether loss of Nrx-1 results in elevated levels of reactive oxygen
species (ROS)
Mitochondria are a major cellular source of reactive oxygen species (ROS);
during OXPHOS, oxygen is metabolized through a series of reductive steps to generate
ATP, and at the same time ROS, such as superoxide anion, hydroxyl radical and
hydrogen peroxide, and reactive nitrogen species are formed (78,225). Excessive ROS
production by defective OXPHOS machinery, leading to an imbalance of ROS and
antioxidants, can result in oxidative stress. Oxidative stress leads to tissue damage and
cell death, which can be especially detrimental for the brain (81). The brain is especially
vulnerability to oxidative damage compared to other organs, due to its high oxidative
demand, as well as its low antioxidant enzyme activity, and a high concentration of
polyunsaturated fatty acids in the myelin sheath and cell membranes, which are highly
susceptible to peroxidation (81). Interestingly, several studies have reported enhanced
levels of markers of oxidative stress in autistic individuals (27,28,151,226,227). As a
result, increased oxidative stress has been proposed to be involved in the underlying
pathophysiology of autism (25,27,28,78,151,225,228).
To our knowledge, neurexin-1 has yet to be linked to increased oxidative stress
in the clinical autism population or in animal models. However, in C. elegans it was
reported that neuroligin-deficient mutants are hypersensitive to oxidative stress,
suggesting an increased basal level of oxidative stress in these animals (229).
Neuroligin is well known as a post-synaptic binding partner of neurexin in the
coordination of many synaptic properties and phenotypes (230–232), raising the
possibility that neurexin-null mutants may show a similar increased sensitivity to
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oxidative stress. Additionally, given that the Nrx-1 mutants exhibit alterations in NAD+
levels and mitochondrial morphology, it is possible that OXPHOS may be disrupted and
could generate elevated ROS. To test this hypothesis, future experiments can utilize well
established methods to directly measure ROS in the Nrx-1 mutant Drosophila (233,234).
Additionally, indirect markers of oxidative stress, such as the abundance of lipid
peroxidation and protein oxidation can be measured as a proxy for ROS levels.
Assessing potential oxidative stress in the Nrx-1 mutants could give more insight into
mitochondrial dysfunction in these flies, as well as point to potential underlying
pathophysiology for the autism-related behavioral phenotypes we observed as well.
Moreover, if ROS were found to be elevated in the Nrx-1 mutants, it would be interesting
to assess whether genetic interventions or pharmacological treatment with antioxidants
are sufficient to normalize ROS levels and improve stress resistance and/or seizure-like
activity in the Nrx-1 mutants.

Concluding remarks
In the autism field, there is an increasing appreciation for the contribution of
metabolic and mitochondrial dysfunction to the pathophysiology of autism. However,
studies investigating the connection between autism and metabolic dysfunction still
comprise a small portion of the research being performed in the autism field. The idea
that metabolic dysfunction may contribute to autism is not a new idea, with reports of
phenylketonuria in patients with autistic-like symptoms in 1969, and lactic acidosis in 4
autistic patients later in 1985 (58,59). Despite the advances that have been made since
these early reports, it is still unclear exactly how alterations in energy metabolism and
mitochondrial function arise in autism and how they may contribute to the condition,
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especially in cases where there is no pathogenic mutation in mitochondrial or nuclear
DNA directly impacting mitochondrial function. Additionally, there are few drugs targeting
mitochondria that are currently in human trials for disorders such as Rett Syndrome,
Fragile X Syndrome, and other forms of autism. Continuing investigation is necessary to
better understand how mitochondrial dysfunction arises in autism in order to aid the
development of targeted therapeutics for this subgroup of autistic individuals with cooccurring metabolic dysfunction.
In Chapter 2, I demonstrated how loss of neurexin-1, a gene significantly
implicated in autism, results in metabolic, mitochondrial, and behavioral alterations in
Drosophila. These results are exciting and valuable as they not only point to a novel role
for neurexin-1 as a regulator of energy metabolism, but they are also one of the few
examples of metabolic dysfunction in an animal model for idiopathic autism, and not a
syndromic form of autism. These data may also bolster future studies aimed to uncover
converging mechanistic links or common molecular pathways that regulate energy
metabolism and mitochondrial function in autism animal models. In this Chapter, I
described several promising routes for future investigation based on the foundation built
in Chapter 2, which have the potential to reveal clinically relevant mechanistic links
between metabolism and behavioral output in autism. Particularly, better understanding
how the metabolic and mitochondrial deficits underlie the behavioral alterations
observed in the Nrx-1 mutant flies could help to uncover novel targets for therapeutic
interventions for autistic individuals. These targeted therapies could be especially
beneficial for specific subgroups of autistic individuals, for example those with cooccurring mitochondrial dysfunction who also experience a higher prevalence of
seizures. While autism and mitochondrial functioning are both incredibly complex areas
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of investigation, the utility of animal models such as Drosophila benefit the field greatly to
ultimately discover novel therapeutic targets and key insights into the pathophysiology of
autism.
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APPENDIX A: THE METABOLOMIC PROFILE OF PRIMARY METABOLITES AND
COMPLEX LIPIDS IN NRX-1-NULL DROSOPHILA

Introduction
Alterations in the metabolomic profile of Nrx-1 mutant Drosophila were presented
in Chapter 2, although only metabolites that were significantly altered in both the Nrx1273/273 and the Nrx-1241/241 flies compared to wild-type flies were included. This Appendix
contains the complete list of known primary metabolites and complex lipids that were
analyzed at the West Coast Metabolomics Center at the University of California, Davis.
The hypothesis, experimental design, and discussion of these metabolomics
experiments can be found in Chapter 2.

Results
Tables A.1 and A.2. List of known primary metabolites and complex lipids profiled
in the Nrx-1 metabolomics study. In the interest of brevity, this large dataset has been
uploaded as a spreadsheet online in ProQuest. A Mann-Whitney U test with false
discovery rate corrected P value was used to identify significant differences in metabolite
levels between Nrx-1273/273 and iso31Bw- flies, Nrx-1241/241 and iso31Bw- flies, and Nrx1273/273 and Nrx-1241/241 flies. Boxes shaded in red indicate a significant difference
(P<0.05) in metabolite levels between the two groups compared in that column. Fold
change is also listed for Nrx-1273/273 vs. iso31Bw- controls, and Nrx-1241/241 vs. iso31Bwcontrols.
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APPENDIX B: FEMALE NRX-1-NULL DROSOPHILA EXHIBIT DECREASED LIPID
AND CARBOHYDRATE STORES, BUT NO CHANGE IN STARVATION RESISTANCE
COMPARED TO FEMALE WILD-TYPE CONSPECIFICS

Rationale
While estimates of the male-to-female ratio of autism in the clinical population
have consistently reported a ratio of 4:1 (1), there is increasing belief among the field
that these estimates may be inaccurate and that the ratio is actually much lower due to
autistic females going undiagnosed (33,34). Recent findings have suggested that the
true male-to-female ratio is 3:4, suggesting that female autistic individuals actually
account for a larger portion of cases (31). A potential explanation for the underdiagnosis
of autistic females is that the clinical presentation of autistic females may be
fundamentally different from that in autistic males. The experiments presented in
Chapter 2 were all performed with male Nrx-1-null flies. We were interested to probe
whether Nrx-1 mutant female flies also show metabolic alterations like their male
counterparts to assess for potential sex differences. To assess the metabolic status of
Nrx-1-null female flies, I performed starvation resistance experiments, as well as
triglyceride and glycogen measurements with Nrx-1273/273, Nrx-1241/241, and iso31Bwvirgin females.

Hypothesis
It is plausible that loss of Nrx-1 in female Drosophila will disrupt energy
homeostasis as it does in male Nrx-1 mutant flies, thus I hypothesized that Nrx-1-null
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female flies would exhibit decreased resistance to starvation, as well as decreased lipid
and carbohydrate stores.
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Results

Figure B.1 Loss of Nrx-1 in female flies does not alter starvation resistance. 3-to-5day old virgin female flies of each genotype were loaded into circadian tubes with 0%
sucrose agar, and then time of death was measured using the Drosophila Activity
Monitoring (DAM) System by recording the time of the last observed activity count. Logrank Mantel Cox test revealed no significant difference in starvation resistance between
female Nrx-1273/273, Nrx-1241/241, and iso31Bw- flies. Sample number (N) per genotype:
iso31Bw- = 40, Nrx-1273/273 = 32, Nrx-1241/241 = 42. Values represent percentage ± SE.
“ns” = not significant.
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Figure B.2 Nrx-1-null female flies have decreased triglyceride levels compared to
wild-type flies. Triglyceride levels were measured in 3-to-5-day old virgin female flies of
each genotype. The resultant values were normalized to protein content. Fly heads were
removed prior to homogenization. Sample number (N) per genotype: iso31Bw- = 15,
Nrx-1273/273 = 14, Nrx-1241/241 = 15. Each sample contained 3 fly bodies. One-way ANOVA
with Tukey’s multiple comparisons post-hoc test indicated that female Nrx-1-null mutant
flies have significantly decreased triglycerides (P<0.0001) compared to iso31Bw- female
control flies. Data shown represents the cumulative results of 3 independent
experiments. Values represent mean ± SEM. **** = P<0.0001
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Figure B.3 Loss of Nrx-1 in female Drosophila results in decreased glycogen
levels. Glycogen levels were measured in 3-to-5-day old virgin female flies of each
genotype. The resultant values were normalized to protein content. Fly heads were
removed prior to homogenization. Sample number (N) per genotype: iso31Bw- = 15,
Nrx-1273/273 = 15, Nrx-1241/241 = 15. Each sample contained 4 fly bodies. One-way ANOVA
with Tukey’s multiple comparisons post-hoc test indicated that female Nrx-1-null mutant
flies have significantly decreased glycogen levels compared to iso31Bw- female control
flies. Data shown represents the cumulative results of 3 independent experiments.
Values represent mean ± SEM. * = P<0.05, **** = P<0.0001
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Discussion
Various studies have attempted to illuminate whether autism presents differently
in male and female autistic individuals, which have resulted in many conflicting findings,
likely owing to the heterogeneity of autism as a whole (235). For example, disagreeing
reports of sex-specific presentations have been described for many behavioral
measures, including social communication, repetitive behaviors, cognition, hyperactivity,
aggression, and more (235–237). We were interested to see whether Nrx-1 mutant male
and female Drosophila both show deficits in starvation resistance and energy
homeostasis.
We found that Nrx-1-null females do not have decreased starvation resistance
compared to female wild-type conspecifics, despite having decreased triglyceride and
glycogen stores. There could be a few potential explanations for these results. We
noticed that the median survival time for iso31bw- females versus iso31bw- males was
lower, wherein the wild-type virgin females had a median survival time of 35 hours
(Figure B.1) whereas wild-type males had a median survival time of 45 hours (Chapter 2
Figure 2.1). This finding was surprising to us given that it has been established in the
field that females typically survive longer than male conspecifics during starvation
because they have a larger body size and more energy stores (238). Conversely, male
and female Nrx-1 mutant flies had more similar median survival times during starvation,
with male Nrx-1 mutants surviving 30-33 hours (Chapter 2 Figure 2.1) and female Nrx-1
mutants surviving a median of 30.5 hours (Figure B.1). It is possible that the decreased
survival time in female iso31Bw- control flies compared to their male counterparts is due
to the nutritional and metabolic costs of reproductive functions, such as egg laying. This
could render the wildtype females more susceptible to starvation stress than wildtype
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males. It is possible that our findings show a “floor effect” where loss of Nrx-1 is unable
to render female flies even more susceptible to starvation, resulting in similar starvation
resistance between Nrx-1 females and iso31Bw- control females. Despite this, these
studies indicate that lipid and carbohydrate metabolism is altered in female Nrx-1-null
Drosophila which closely mimics our findings in male Nrx-1-null flies, suggesting that
loss of Nrx-1 does not have sex-specific effects on energy homeostasis.

Materials and methods
Fly genetics and husbandry
Fly strains that contain the Nrx-1273 and Nrx-1241 alleles are described in Li et al., (109).
These flies were outcrossed in the w1118(iso31Bw-) background for 6 generations and
maintained over a third chromosome balancer to avoid recombination events. The fly
strains were cultured on a standard cornmeal molasses medium and maintained in the
presence of 12h light: 12h dark (LD) cycle at 25°C.

Starvation Stress
Virgin female flies were collected 0 days post eclosion and entrained to a stringent 12h
light: 12h dark cycle for 3-4 days at 25°C. Flies were then placed in individual glass
tubes containing 0% sucrose, 2% agar, and loaded into activity monitors (Trikinetics,
DAM2 system, Waltham, MA) that were then returned to a 12h light: 12h dark light cycle
at 25°C. The experiment was concluded when all flies were confirmed dead. Time of
death after the onset of starvation was determined by the final activity count recorded by
the activity monitors.
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Triglyceride Measurement
Measurement of triglycerides was performed as described in Weisz et al., (72). Briefly,
3- to 5-day-old adult virgin female flies were collected on dry ice at approximately ZT0ZT1. Samples for triglyceride measurement contained 3 flies each, and fly heads were
removed prior to homogenization. Fly bodies were homogenized in lysis buffer that
contained 140mM NaCl, 50mM Tris-HCl (pH 7.4), 20% Triton X-100, and 1X protease
inhibitors (Roche, Indianapolis, IN). The homogenate was then centrifuged at 15871 x g
for 10 minutes at 4°C. Triglyceride concentration for each sample was determined in
triplicate using the Triglyceride LiquiColor kit (Stanbio Laboratory, Boerne, TX), and was
normalized to protein content using the Pierce BCA Protein Assay Kit (Thermo Scientific,
Rockford, IL).

Glycogen measurement
Measurement of glycogen was performed as described in Weisz et al., (72). Briefly, 3- to
5-day-old adult virgin female flies were collected on dry ice at approximately ZT0-ZT1.
Samples each had 4 decapitated fly bodies, which were homogenized in 200µL of 0.1M
NaOH. The homogenate was centrifuged at 15871 x g for 10 minutes at 4°C. The
supernatant was extracted from each sample and 20 µL of the lysate was treated with 5
mg/mL Amyloglucosidase (Sigma- Aldrich, Saint Louis, MO) in 0.2 M acetate, pH 4.8, as
this enzyme catabolizes glycogen to yield free glucose molecules. Concurrently, another
20 µL aliquot of the lysate was treated with 0.2 M acetate, pH 4.8 alone. Both reactions
incubated for 2h at 37°C. Subsequently, the free glucose content in each reaction was
measured in triplicate with the Amplex Red Glucose/ Glucose Oxidase Assay kit
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(Molecular Probes, Eugene, OR). The glycogen concentration of each sample was
determined by subtracting the values of free glucose in the untreated samples. The
protein concentration of these reactions was then determined with the Pierce BCA
Protein Assay Kit (Thermo Scientific, Rockford, IL) for normalization.

Statistics
The Prism software package (GraphPad Software, v9.2.0) was used to generate graphs
and perform statistical analyses. The log-rank (Mantel-Cox) test was used to examine
differences in starvation stress resistance between genotypes. One-way analysis of
variance (ANOVA) with post hoc Tukey tests was used to assess differences in
triglyceride levels and glycogen levels across genotypes.
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APPENDIX C: PHARMACOLOGICAL OR DIETARY INTERVENTION DOES NOT
RESCUE STARVATION RESISTANCE TO WILD-TYPE LEVELS IN NRX-1-NULL
DROSOPHILA

Rationale
In Chapter 2, I established that loss of Nrx-1 leads to decreased starvation
resistance and altered energy metabolism. However, it is unclear how Nrx-1 regulates
energy homeostasis or resistance to nutrient deprivation. In attempts to obtain clues to
these questions, I performed several experiments in which I supplied either
pharmacological agents or dietary supplements to assess whether starvation resistance
in the Nrx-1 mutants could be improved back to wild-type levels. In doing so, I could
identify a pathway by which Nrx-1 regulates energy metabolism and stress resistance.

Hypothesis
I hypothesized that treatment with pharmacological agents or a special diet, such
as NAD+ precursors, Rolipram, and a high sucrose diet, would improve starvation
resistance in the Nrx-1 mutants compared to wild-type conspecifics.

Results
NAD+ precursors
In Chapter 2, I demonstrated that the Nrx-1 mutants show decreased NAD+ levels
and a decreased NAD+/NADH ratio, and I explored whether treating the Nrx-1 mutants
with NAD+ precursors would be sufficient to improve starvation resistance. Diminished
NAD+ levels have previously been shown to be involved in the development of
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behavioral, mitochondrial, and metabolic disorders (170–176), while the administration of
NAD+ precursors has been shown to increase NAD+ levels and prevent metabolic
disease (170–176). In this Appendix, I have included more detail pertaining to the design
of these NAD+ precursor treatment experiments.
To assess whether decreased NAD+ levels underlie the diminished stress
resistance in the Nrx-1 mutants, I administered NAD+ precursors, specifically
nicotinamide riboside (NR) or nicotinamide (NAM), in the food of Nrx-1-null flies and
wild-type conspecifics during development and/or adulthood prior to the starvation
period. I anticipated that treatment with NAD+ precursors would enhance starvation
resistance in the Nrx-1 mutants.
I first assessed whether adulthood treatment with 500 μM NR improves
starvation resistance in the Nrx-1 mutant flies. Both Nrx-1-null flies and iso31Bw- flies
were raised on normal fly food, and they were subsequently collected into vials with fly
food containing 500 μM NR from day 0-1 post-eclosion until the flies were 3-to-5-days
old. The flies were then placed into circadian tubes containing 0% sucrose, 2% agar for
the starvation experiment. I found that treatment with 500 μM NR during adulthood did
not impact starvation resistance in iso31Bw-, Nrx-1273/273, nor Nrx-1241/241 flies (Figure
C.1).
I next evaluated whether NAM supplementation during development and
adulthood was able to improve starvation resistance in the Nrx-1 mutants. For these
experiments, Nrx-1-null and iso31Bw- flies were raised on food that contained 30mg
NAM/100g food, and they were subsequently placed into vials containing 30mg
NAM/100g food from day 0-1 post-eclosion until the flies were 3-to-5-days old. The flies
were then placed into circadian tubes containing 0% sucrose agar for the starvation
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experiment. I found that treatment with NAM during development and adulthood was not
sufficient to increase starvation resistance to wild-type levels in Nrx-1273/273 and Nrx1241/241 flies (Figure C.2). In fact, Nrx-1273/273 flies treated with NAM showed significantly
worsened starvation resistance compared to vehicle treated counterparts.
There are several potential explanations as to why treatment with NR or NAM
was insufficient to rescue starvation resistance in the Nrx-1-null mutants. First, the
dosages used in these experiments may not have been sufficient for the improvement
NAD+ levels, and thus starvation resistance. We did not perform NAD+ measurements on
flies treated with NR or NAM, thus we are unable to determine whether NAD+ levels
were significantly improved after treatment. Second, the timing of NR or NAM treatment
may not have been optimal for the improvement of starvation resistance. For example,
NAD+ precursor supplementation may be required for a longer period of time in order to
significantly improve stress resistance. Another possibility is that NAD+ precursor
supplementation could be required during the pupal period, during which pupae do not
feed and therefore would not have been consuming food spiked with NR or NAM. It may
be beneficial to assess a range of dosages and treatment timing of NAD+ precursors in
future experiments to provide a more complete picture how decreased NAD+ levels in
the Nrx-1 mutants contribute to the observed metabolic phenotypes. Additionally, future
studies could assess whether genetic methods to augment NAD+ levels can improve
starvation resistance in the Nrx-1 mutants, for example by overexpressing NAD+ salvage
enzymes that recycle NAD+ precursors back to NAD+ (239–241). This genetic approach
would also allow for experimental manipulation of NAD+ levels during the pupal period,
which drug treatments in food cannot target.
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Furthermore, it possible that treatment with NAD+ precursors alone is insufficient
to improve starvation resistance, as it was demonstrated in Chapter 2 that the Nrx-1
mutants exhibit several deficits in energy stores as well as mitochondrial morphology. It
may be possible that the deficit in starvation resistance is due to a combination of
factors, for which NAD+ precursors alone may not be sufficient for rescue. To this end, it
would be worthwhile to assess whether NAD+ precursors are able to improve other
metabolic, mitochondrial, or behavioral phenotypes in the Nrx-1 mutants. Moreover, the
diminished NAD+ levels we observed in the Nrx-1 mutants may not be solely explained
by alterations in NAD+ biosynthesis, as the total pool size of NAD+ depends on the
relative rates of synthesis and degradation. In addition to possible alterations in NAD+
biosynthesis, there may be an imbalance in NAD+ consumption due to aberrations in
other metabolic pathways in which NAD+ is a cofactor, which is another possible area of
future investigation. Thus, from these experiments we cannot definitively conclude that
diminished NAD+ levels causally underlie the observed metabolic and behavioral
phenotypes seen in the Nrx-1-null mutants. However, there are additional experiments
that are yet to be performed to further explore this hypothesis.

Rolipram
Another pharmacological intervention that I assessed was treatment with
Rolipram, which is a phosphodiesterase-4 (PDE-4) inhibitor. PDE-4 degrades cyclic
adenosine 3, 5′-monophosphate (cAMP) by hydrolyzing it to 5’ AMP, and is the most
abundant cAMP-specific PDE in the brain of flies and mammals (242). cAMP is a
versatile second messenger involved in several biological processes, including cellular
migration, differentiation, proliferation, and apoptosis. Importantly, cAMP signaling is
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also involved in regulating energy homeostasis, mitochondrial dynamics, and
mitochondrial biogenesis in response to extracellular or intracellular cues or even
environmental stressors (243–245). It has been shown previously that cAMP levels are
reduced in animal models of Fragile X Syndrome as well as in patient derived cell lines,
and the augmentation of cAMP levels either genetically or with PDE4 inhibition can
improve behavior and cognition in a Drosophila Fragile X model (246–250). Given the
similarities that we found in metabolic alterations between Nrx-1-null flies and the
Drosophila model of Fragile X Syndrome in our lab, we hypothesized that the metabolic
phenotypes we observed in the Nrx-1 mutants could be ameliorated by PDE4 inhibition
using Rolipram. For these experiments, I assessed whether treatment with Rolipram
during adulthood would improve starvation resistance. Adult male flies were raised on
normal fly food and then were collected onto food with 50 μM Rolipram for 6-8 days
post-eclosion before being loaded into circadian tubes with 0% sucrose for the starvation
experiment. I found that adulthood treatment with 50 μM Rolipram was not sufficient to
rescue starvation resistance to wild-type levels in the Nrx-1 homozygous mutant flies
(Figure C.3). Again, it is possible that the dosage or timing of drug delivery was not
optimal for the improvement of starvation resistance in the Nrx-1-null flies, which could
be further probed in future experiments. The Jongens lab has previously shown that a
higher dose of 100μM Rolipram was sufficient to improve cAMP levels in Fmr1-null flies
(246), thus it is possible that this higher dosage would be optimal for the Nrx-1 mutants
as well.
Other options to assess whether dysregulated cAMP signaling is involved in the
metabolic alterations seen in the Nrx-1 mutants could be to try treatment with lithium or
metabotropic glutamate receptor (mGluR) antagonists, which also upregulate cAMP
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signaling. Lithium inhibits glycogen synthase kinase-3beta (GSK-3β), which is a negative
regulator of protein kinase A (PKA), which is part of the cAMP signaling cascade. In
mammals, mGluRs are G-protein coupled receptors that couple predominantly to Gi
signaling. Gi signaling suppresses adenylate cyclase (AC) activity, which is important for
the generation of cAMP. mGluR antagonists block Gi suppression of AC activity, thereby
augmenting cAMP levels. The use of lithium and mGluR antagonists have both been
shown to rescue impairments in Fragile X models (247,249,251,252). It may be
worthwhile to assess these additional manipulations in the Nrx-1 mutants, as it is
possible that Nrx-1 could potentially regulate cAMP signaling through trans-synaptic
interactions which could then affect mitochondrial energy metabolism.

Dietary intervention—High sucrose diet
In Chapter 2, I presented data demonstrating that loss of Nrx-1 results in
alterations in carbohydrate metabolism, with reduced glucose levels and glycogen
stores. I wanted to test the hypothesis that augmenting dietary carbohydrates could
improve starvation stress resistance in Nrx-1-null mutants. If reduced energy stores are
what underlies the increased sensitivity to starvation in Nrx-1 mutants, then it is possible
that increasing carbohydrates by supplying additional sucrose in their food could help to
improve starvation resistance. For these experiments, normal sucrose (1X) and high
sucrose (5X) food was made using a modified recipe from Pasco & Léopold (2012)
(253). Flies of each genotype were fed either 1X sucrose or 5X sucrose food from 0-1
days post-eclosion until they were 3-to-5-days old, after which the starvation experiment
began. All genotypes showed an improvement in starvation resistance after being fed 5X
sucrose food, with significantly longer median survival times compared to treatment with
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1X sucrose food (Figure C.4). Despite this, starvation resistance in Nrx-1 homozygous
mutant flies treated with 5X sucrose food still did not reach that of wild-type flies (Figure
C.4 E-F), suggesting that while dietary supplementation of carbohydrates is beneficial for
survival during starvation that there may be additional underlying alterations in the Nrx-1
mutants that contribute to decreased starvation resistance. It is also possible that the
Nrx-1 mutants require dietary supplementation during both development and adulthood,
rather than solely during adulthood, to show improvement of starvation resistance
comparable to wild-type levels.
Seeing that the Nrx-1-null flies also have decreased triglyceride levels, I
performed experiments in which I supplemented the diet of the Nrx-1 mutants and
controls with 30% coconut oil, as an additional source of lipids. This high amount of
coconut oil was lethal to all genotypes (iso31Bw-, Nrx-1273/273, and Nrx-1241/241) after 3-5
days of treatment during adulthood, and therefore these experiments were not viable. It
is possible that a lower dosage of coconut oil with additional sucrose in their diet could
be beneficial for the metabolic and behavioral phenotypes of the Nrx-1 mutants.
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Results

Figure C.1 Treatment with nicotinamide riboside (NR) during adulthood does not
improve starvation resistance in Nrx-1 mutant Drosophila. (A) Starvation resistance
curve for iso31Bw-, Nrx-1273/273, and Nrx-1241/241 flies treated with either vehicle or NR. (BD) Starvation curves for each genotype from (A) are shown separately for ease of
viewing. Log-rank Mantel Cox test revealed no significant difference between vehicle
treated vs. 500 μM NR treated flies for each genotype. Sample number (N) per group:
iso31Bw- Vehicle = 18, iso31Bw- NR = 18, Nrx-1273/273 Vehicle = 11, Nrx-1273/273 NR = 17,
Nrx-1241/241 Vehicle = 6; Nrx-1241/241 NR = 7. Values represent percentage ± SE.
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Figure C.2 Treatment with nicotinamide (NAM) during development and adulthood
does not improve starvation resistance in Nrx-1 mutant Drosophila. (A) Starvation
resistance curve for iso31Bw-, Nrx-1273/273, and Nrx-1241/241 flies treated with either vehicle
or NAM. (B-D) Starvation curves for each genotype from (A) are shown separately for
ease of viewing. Log-rank Mantel Cox test revealed no significant difference between
vehicle-treated vs. NAM-treated iso31Bw- flies or Nrx-1241/241 flies. Nrx-1273/273 flies
treated with NAM actually showed decreased starvation resistance compared to vehicletreated Nrx-1273/273 flies (P =0.0202). Sample number (N) per group: iso31Bw- Vehicle =
29, iso31Bw- NAM = 31, Nrx-1273/273 Vehicle = 28, Nrx-1273/273 NAM = 28, Nrx-1241/241
Vehicle = 15; Nrx-1241/241 NAM = 20. Values represent percentage ± SE.
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Figure C.3 Treatment with Rolipram does not improve starvation resistance in Nrx1-null Drosophila. (A) Starvation resistance curve for iso31Bw-, Nrx-1273/273, and Nrx1241/241 flies treated with either ethanol-vehicle food or Rolipram food. (B-D) Starvation
curves for each genotype from (A) are shown separately for ease of viewing. Log-rank
Mantel Cox test revealed no significant difference between vehicle-treated vs. Rolipramtreated iso31Bw-, Nrx-1273/273 , or Nrx-1241/241 flies. Sample number (N) per group:
iso31Bw- Vehicle = 30, iso31Bw- Rolipram = 30, Nrx-1273/273 Vehicle = 25, Nrx-1273/273
Rolipram = 26, Nrx-1241/241 Vehicle = 18; Nrx-1241/241 Rolipram = 19. Values represent
percentage ± SE.
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Figure C.4 Increasing sucrose content in the diet of Nrx-1-null flies improves
starvation resistance, but not to wild-type levels. (A) Starvation resistance curve for
iso31Bw-, Nrx-1273/273, and Nrx-1241/241 flies fed either 1X sucrose food or 5X sucrose
food. (B-D) Starvation curves for each genotype from (A) are shown separately for ease
of viewing. Log-rank Mantel Cox test revealed that 5X sucrose food improved starvation
resistance for iso31Bw-, Nrx-1273/273 , and Nrx-1241/241 flies compared to 1X sucrose food.
(E-F) Starvation curves for Nrx-1273/273 flies (red) or Nrx-1241/241 flies (blue) on 5X sucrose
food versus iso31Bw- flies on 1X sucrose food (black). Log-rank Mantel Cox tests
revealed that iso31Bw- flies on 1X sucrose food still have increased starvation
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resistance compared to either Nrx-1273/273 or Nrx-1241/241 flies on 5X sucrose food. Sample
number (N) per group: iso31Bw- 1X sucrose = 48, iso31Bw- 5X sucrose = 48, Nrx1273/273 1X sucrose = 53, Nrx-1273/273 5X sucrose = 52, Nrx-1241/241 1X sucrose = 36; Nrx1241/241 5X sucrose = 40. Values represent percentage ± SE. ** = P<0.01, *** = P<0.001,
**** = P<0.0001

Discussion
This appendix demonstrated that the pharmacological and dietary interventions
given to Nrx-1-null Drosophila were insufficient to rescue starvation resistance to wildtype levels. The goal of these experiments was to uncover a potential mechanism by
which Nrx-1 regulates energy homeostasis and stress resistance, although treatment
with NAD+ precursors, Rolipram, or enhanced dietary sucrose were unable to improve
starvation resistance back to wild-type levels. The full range of possible drug dosages
and delivery timing were not completely exhausted in this set of preliminary experiments.
Thus, while the current dataset cannot definitively pinpoint a potential pathway by which
Nrx-1 regulates starvation resistance, there are additional experiments that could be
performed to elucidate answers to this question.

Materials and Methods
Fly genetics and husbandry
Fly strains that contain the Nrx-1273 and Nrx-1241 alleles are described in Li et al., (109).
These flies were outcrossed in the w1118(iso31Bw-) background for 6 generations and
maintained over a third chromosome balancer to avoid recombination events. The fly
strains were cultured on a standard cornmeal molasses medium (unless otherwise
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specified in the following Drug Treatment section) and maintained in the presence of 12h
light: 12h dark (LD) cycle at 25°C.

Drug Treatments
Nicotinamide Riboside—NR was obtained from Sigma (SMB00907) and solubilized in
water before adding to standard cornmeal molasses food at a final concentration of 500
μM NR. Flies were raised on normal fly food, and they were subsequently collected into
vials with fly food containing 500 μM NR from day 0-1 post-eclosion until the flies were 3to-5-days old.
Nicotinamide—NAM was obtained from Sigma (481907) and solubilized in water before
adding to standard cornmeal molasses food at a final concentration of 30mg NAM/100g
medium. Flies were raised on food that contained 30mg NAM/100g food, and they were
subsequently placed into vials containing 30mg NAM/100g food from day 0-1 posteclosion until the flies were 3-to-5-days old.
Rolipram—Rolipram was obtained from AG Scientific (R-1012) and was solubilized in
ethanol prior to adding it to standard cornmeal molasses food at a final concentration of
50 μM. Flies were raised on normal fly food and then were collected onto food with either
ethanol vehicle or 50 μM Rolipram for 6-8 days post-eclosion.
1X and 5X sucrose food—The protocol for preparation of normal (1X) and high (5X)
sucrose food was modified from Pasco and Léopold 2012 (253) and is included in
Appendix E. Flies were raised on a standard cornmeal-molasses medium and placed on
either 1X sucrose food or 5X sucrose food from 0-1 days post-eclosion until they were 3to-5-days old.
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Starvation stress
Male flies were collected 0-1 days post eclosion and entrained to a stringent 12h light:
12h dark cycle for 3-4 days at 25°C. Flies were then placed in individual glass tubes
containing 0% sucrose, 2% agar, and loaded into activity monitors (Trikinetics, DAM2
system, Waltham, MA) that were then returned to a 12h light: 12h dark light cycle at
25°C. The experiment was concluded when all flies were confirmed dead. Time of death
after the onset of starvation was determined by the final activity count recorded by the
activity monitors.

Statistics
The Prism software package (GraphPad Software, v9.2.0) was used to generate graphs
and perform statistical analyses. The log-rank (Mantel-Cox) test was used to examine
differences in starvation stress resistance between groups.
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APPENDIX D: SPATIAL MAPPING EXPERIMENTS USING GENETIC CONSTRUCTS
FOR KNOCKDOWN OR RESCUE OF NRX-1 EXPRESSION FAILED TO PRODUCE
RELIABLE ALTERATIONS IN STARVATION RESISTANCE

Rationale
In Chapter 2, I established that Nrx-1 modulates energy homeostasis and
resistance to nutrient-deprivation stress. In adult Drosophila, Nrx-1 is expressed broadly
throughout the central nervous system, as well as in motor neurons, muscle, gut,
salivary glands, wings, and legs (137,138). It is currently unclear how or in what cell type
Nrx-1 may exert its role as a regulator of energy metabolism. To gain insights into these
questions, I utilized the UAS/GAL4 system in Drosophila to either knockdown or rescue
Nrx-1 expression in a cell-type specific manner, and then performed starvation stress
experiments. In doing so, I could potentially identify where in the fly body Nrx-1
expression is necessary or sufficient for resistance to nutrient-deprivation stress.

Results
RNAi knockdown
For knockdown of Nrx-1 expression, I first obtained two UAS-Nrx-1-RNAi
constructs from the Bloomington Drosophila Stock Center (BDSC) at Indiana University,
UAS-Nrx-1-RNAi-JF02652 (BDSC #27502) and UAS-Nrx-1-RNAi-HMS00403 (BDSC
#32408). Initially, my goal was to use these RNAi constructs to knockdown Nrx-1 gene
expression ubiquitously to ensure that RNAi-mediated knockdown of Nrx-1 recapitulated
the decreased resistance to starvation stress that we observed in the Nrx-1-null flies in
Chapter 2. For ubiquitous expression of the UAS-Nrx-1-RNAi constructs, I performed
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genetic crosses with Daughterless-GAL4 or Actin-GAL4. Additionally, I utilized the
following control lines from the BDSC Transgenic RNAi Project for these experiments:
UAS-luciferase-RNAi (BDSC #35788), UAS-GFP-RNAi (BDSC #35786), and the y1v1
genetic background control (BDSC #1509). All RNAi experiments were performed with
heterozygous UAS-Nrx-1-RNAi or control UAS constructs, and heterozygous
Daughterless-GAL4 or Actin-GAL4. I found that flies with ubiquitous expression of UASNrx-1-RNAi driven by Daughterless-GAL4 or Actin-GAL4 did not recapitulate the Nrx-1null mutant phenotype compared to controls (Figures D.1 and D.2). In these
experiments, if ubiquitous Nrx-1 knockdown were to successfully recapitulate the Nrx-1
mutant phenotype, I would have expected significantly diminished starvation resistance
compared to controls. However, I found that flies with ubiquitously expressed UAS-Nrx1-RNAi mostly overlapped with control flies in median survival times during starvation.
These findings suggested that these UAS-Nrx-1-RNAi constructs may not induce
sufficient knockdown of Nrx-1 expression to fully recapitulate the Nrx-1-null mutant
phenotype during starvation. Therefore, I could not continue forward with these
experiments investigating the cell-type in which Nrx-1 expression is required for
starvation resistance using these RNAi reagents. The laboratory has since obtained
additional UAS-Nrx-1-RNAi constructs from the Vienna Drosophila Resource Center
(VDRC), UAS-Nrx-1-RNAi-GD14451 (VDRC #36326 and #36328) and UAS-Nrx-1RNAi-GD2619 (VDRC #4306), with which we hope to reassess these experiments and
continue our efforts in mapping where in the fly Nrx-1 exerts its control of energy
metabolism.

UAS-Nrx-1 Rescue
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We continued our spatial mapping efforts with the UAS/GAL4 system by using a
UAS-Nrx-1 rescue construct to restore Nrx-1 expression in a cell-type specific manner in
Nrx-1-null flies. We obtained the UAS-Nrx-1 construct that was originally described in
Zeng et al. (2007) (108). For these rescue experiments, we wanted to assess whether
Nrx-1 exerts its control of energy homeostasis via cell-non-autonomous actions in the
central nervous system. To do this, we utilized an elav-GAL4 for pan-neuronal
expression of the UAS-Nrx-1 rescue construct, or a tdc2-GAL4 construct for rescue of
Nrx-1 expression in octopamine neurons. Octopamine is the invertebrate equivalent of
norepinephrine, and it has been shown to have a crucial role in the regulation of
starvation resistance and metabolism in Drosophila (212,213). Thus, we hypothesized
that Nrx-1 may act in neurons, specifically octopamine neurons, to regulate starvation
resistance via cell-non-autonomous mechanisms. Unfortunately, we found that the Nrx-1
mutants containing the UAS-Nrx-1 transgene alone, without the elav-GAL4 or the tdc2GAL4, showed improved starvation resistance, suggesting that the UAS-Nrx-1 construct
exhibited leaky expression and produced some Nrx-1 (Figures D.3 and D.4). These
experiments are difficult to interpret, given that the leakiness of the UAS-Nrx-1 produces
uncontrolled expression of Nrx-1 and confounds our experimental results. Our laboratory
has since obtained a different UAS-Nrx-1 that was originally described in Li et al (2007)
(109). We hope to be able to perform further spatial mapping experiments with this UASNrx-1 rescue construct to determine where Nrx-1 expression is sufficient for starvation
resistance.
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Figure D.1 Ubiquitous RNAi-mediated knockdown of Nrx-1 driven by
Daughterless-GAL4 does not result in decreased starvation resistance. Starvation
resistance curve for control flies shown in white (UAS-luciferase-RNAi, UAS-GFP-RNAi,
or the y’v’ genetic background crossed with Daughterless-GAL4), and Nrx-1 knockdown
flies shown in red (UAS-Nrx-1-RNAi-JF02652 and UAS-Nrx-1-RNAi-HMS00403 crossed
with Daughterless-GAL4). Sample number (N) per group: UAS-luciferase-RNAi>DaGAL4 = 32, y1v1> Da-GAL4 = 19, UAS-GFP-RNAi>Da-GAL4= 31, UAS-Nrx-1-RNAiJF02652>Da-GAL4= 20, UAS-Nrx-1-RNAi-HMS00403>Da-GAL4 = 16. Values represent
percentage ± SE.
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Figure D.2 Ubiquitous RNAi-mediated knockdown of Nrx-1 driven by Actin-GAL4
does not result in decreased starvation resistance. Starvation resistance curve for
control flies shown in white (UAS-luciferase-RNAi, UAS-GFP-RNAi, or the y1v1 genetic
background crossed with Actin-GAL4), and Nrx-1 knockdown flies shown in red (UASNrx-1-RNAi-JF02652 and UAS-Nrx-1-RNAi-HMS00403 crossed with Actin-GAL4).
Sample number (N) per group: UAS-luciferase-RNAi>Actin-GAL4 = 17, y’v’>Actin-GAL4
= 20, UAS-GFP-RNAi>Actin-GAL4= 25, UAS-Nrx-1-RNAi-JF02652>Actin-GAL4= 19,
UAS-Nrx-1-RNAi-HMS00403>Actin-GAL4 = 22. Values represent percentage ± SE.
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Figure D.3 The UAS-Nrx-1 construct for rescue of Nrx-1 expression shows
improvement in starvation resistance in the absence of the elav-GAL4 driver,
indicating leaky expression. Starvation resistance curve for each genotype is shown.
Flies expressing only the UAS-Nrx-1 construct in the Nrx-1241/241 mutant background
(UAS-Nrx-1, Nrx-1241/241, shown in brown) exhibit improved starvation resistance
compared to Nrx-1273/273 (red) and Nrx-1241/241 flies (blue) (P <0.0001). Additionally, flies
expressing both elav-GAL4 and UAS-Nrx-1 (black) show an even greater improvement
in starvation resistance, comparable to that of iso31Bw- flies. Sample number (N) per
group: iso31Bw- = 59, Nrx-1273/273 = 49, Nrx-1241/241 = 34, UAS-Nrx-1, Nrx-1241/241 = 34,
elav-GAL4/+; UAS-Nrx-1, Nrx-1241/241 = 45. Values represent percentage ± SE.

126

Figure D.4 The UAS-Nrx-1 construct for rescue of Nrx-1 expression shows
improvement in starvation resistance in the absence of the tdc2-GAL4 driver,
indicating leaky expression. Starvation resistance curve for each genotype is shown.
Flies expressing only the UAS-Nrx-1 construct in the Nrx-1241/241 mutant background
(UAS-Nrx-1, Nrx-1241/241, shown in brown) exhibit improved starvation resistance
compared to Nrx-1273/273 (red) and Nrx-1241/241 flies (blue) (P <0.0001). Flies expressing
both tdc2-GAL4 and UAS-Nrx-1 (black) show an even greater improvement in starvation
resistance compared to the iso31Bw- flies (white) (P <0.0001), suggesting
overexpression of Nrx-1. Moreover, the tdc2-GAL4/+; UAS-Nrx-1, Nrx-1241/241 group
(black) exhibits significantly improved starvation resistance compared to the UAS-Nrx-1,
Nrx-1241/241 group (brown) (P <0.0001). Sample number (N) per group: iso31Bw- = 20,
Nrx-1273/273 = 6, Nrx-1241/241 = 12, UAS-Nrx-1, Nrx-1241/241 = 18, tdc2-GAL4/+; UAS-Nrx-1,
Nrx-1241/241 = 25. Values represent percentage ± SE.
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Discussion
The goal of the experiments in this Appendix was to identify a cell type and/or
neuronal subtype in which Nrx-1 functions to regulate energy metabolism and resistance
to starvation stress. There is ample evidence showing crosstalk between the periphery
and central nervous system in the regulation of nutrient homeostasis in response to
environmental cues (166,254), thus it is possible that Nrx-1 could regulate energy
metabolism via cell-non-autonomous mechanisms. I utilized the UAS/GAL4 system for
either knockdown or rescue of Nrx-1 expression to attempt to gather clues to these
questions. These RNAi knockdown and UAS-Nrx-1 rescue reagents exhibited technical
complications in these experiments, showing either incomplete knockdown or leaky
expression of Nrx-1, respectively. These technical issues hindered the ability to proceed
with these experiments, thus the laboratory has obtained additional reagents to revisit
these hypotheses in the future.

Materials and Methods
Fly genetics and husbandry
Fly strains that contain the Nrx-1273 and Nrx-1241 alleles are described in Li et al., (109).
UAS-Nrx-1-RNAi lines were obtained from Bloomington Drosophila Stock Center: UASNrx-1-RNAi-JF02652 (BDSC #27502) and UAS-Nrx-1-RNAi-HMS00403 (BDSC
#32408). Control lines for RNAi experiments were also from the BDSC: UAS-luciferaseRNAi (BDSC #35788), UAS-GFP-RNAi (BDSC #35786), and the y1v1 genetic
background control (BDSC #1509). All RNAi experiments were performed with
heterozygous UAS-Nrx-1-RNAi or control UAS constructs, and heterozygous
Daughterless-GAL4 or Actin-GAL4. The UAS-Nrx-1 rescue line was originally described
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in Zeng et al. (2007) (108). The fly strains were cultured on a standard cornmeal
molasses medium and maintained in the presence of 12h light: 12h dark (LD) cycle at
25°C.

Starvation stress
Male flies were collected 0-1 days post eclosion and entrained to a stringent 12h light:
12h dark cycle for 3-4 days at 25°C. Flies were then placed in individual glass tubes
containing 0% sucrose, 2% agar, and loaded into activity monitors (Trikinetics, DAM2
system, Waltham, MA) that were then returned to a 12h light: 12h dark light cycle at
25°C. The experiment was concluded when all flies were confirmed dead. Time of death
after the onset of starvation was determined by the final activity count recorded by the
activity monitors.

Statistics
The Prism software package (GraphPad Software, v9.2.0) was used to generate graphs
and perform statistical analyses. The log-rank (Mantel-Cox) test was used to examine
differences in starvation stress resistance between groups.
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APPENDIX E: PROTOCOLS

Fly Food—Full Recipe from Jongens Lab

1) Start heating 2000 mL H2O and add 25.94 g agar
2) Add 510 mL H2O to a beaker and mix in 40 g yeast and 160 g cornmeal
3) When water begins to boil, turn heat down to 1 and add yeast/cornmeal mixture
slowly. Cover pot with tinfoil and let mix for 15 mins.
4) Mix 157.6 mL molasses and 250 mL H2O in a graduated cylinder and add into pot.
Add 70 mL H2O. Let mix for 30 mins.
5) Add 0.8 mL phosphoric acid, 7 mL propionic acid and 25.2 mL 25% tegosept. Mix
for 3 mins then dispense.

To make Tegosept: Add 50g of tegosept into 200mL EtOH
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Modified Fly Food Recipe for 1X sucrose and 5X sucrose food from Pasco and
Léopold Paper (253)

1) Add 750mL ddH2O to pot with stir bar. Turn heat to 10 and stir to 5.
2) Add 10g agar and either 60g (1X) or 300g (5X) sucrose. Add sucrose slowly so it
has time to dissolve. Cover pot with aluminum foil.
3) In a separate container, add 250mL ddH2O. Then add 34g yeast and 82.5g
cornmeal while stirring.
4) Bring liquid to a boil. The food must boil or it will not solidify.
5) Add yeast/cornmeal mixture. Stir before adding so the cornmeal doesn’t clump. Turn
heat to 1.
6) Cook food for 30 minutes.
7) Add 280μL phosphoric acid, 2.5mL propionic acid and 9mL 25% tegosept. Wear
goggles for this step.
8) Allow acids to stir in for 5 minutes, then dispense food into desired containers.
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Glycogen Measurement
Courtesy of Michelle Bland from the Birnbaum Laboratory

Solutions & reagents needed:
0.1 M NaOH
0.2 M acetate, pH 4.8
Amyloglucosidase (AMG), 5 mg/mL in 0.2 M acetate, pH 4.8 (Sigma A7420-25MG)
Amplex Red Glucose/Glucose Oxidase Assay kit (Invitrogen A22189)
Bicinchoninic Acid Protein Assay kit, Peirce
Kontes pestle and tubes

Tissue disruption
1. homogenize flies (4 flies / tube) in 200 μL 0.1 M NaOH using Kontes pestle
2. centrifuge 13,000 rpm, 10 min, 4°C
3. transfer supernatant to new tube

Glycogen assay
1. Set up two sets of reactions:
A) 20 μL lysate + 100 μL 0.2 M acetate, pH 4.8
B) 20 μL lysate + 80 μL 0.2 M acetate, pH 4.8 + 20 μL 5 mg/mL AMG
2. Incubate reactions for 2 hours at 37°C
3. Dilute incubated samples 1:3 in 1X reaction buffer from Amplex Red Kit.
4. Pipette 40 μL each of standards (see below) and 40 μL diluted unknowns into each
well.
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Perform assay in triplicate.

Standards (enough for two plates):
concentration

500 μM glucose

reaction buffer

150 μM

90 μL

210 μL

100

60

240

80

48

252

60

36

264

40

24

276

20

12

288

10

6

294

0

0

300

5. Prepare reaction mix (40 μL for each well).
85 μL

10 mM Amplex Red

170 μL

10 U/mL HRP

170 μL

100 U/mL glucose oxidase

8.075 mL

reaction buffer

6. Add 40 μL reaction mix to each well
7. Incubate 30 minutes, room temperature, protected from light
8. Read in a plate reader at 570 nm

Protein Assay
Measure protein in 20 μL of original lysate using the BCA assay kit.
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Calculations
Glucose level in –AMG samples = free glucose
Glucose level in +AMG samples = free glucose + glycogen
1. Subtract –AMG glucose from +AMG glucose to get glycogen level
2. Calculate amount of free glucose and glycogen in 1 μL of the orginal lysate (see
below)
3. Calculate amount of protein in 1 μL of the original lysate
4. Normalize free glucose and glycogen levels to total protein.
5. Statistics.

As the assay in this protocol is described:
20 μL lysate + 100 μL acetate (+/- AMG)
40 μL incubated lysate (equivalent to 6.7 μL lysate) + 80 μL reaction buffer
40 μL diluted, incubated lysate (equivalent to 2.2 μL lysate) + 40 μL reaction mix
Protein = 2-5 μL of original lysate

To note:
The Amplex Red assay is saturated at high levels of glucose, so you may need to create
a different standard curve or dilute samples more than 1:3.
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Triglyceride assay – Drosophila larvae or adults
Courtesy of Michelle Bland from the Birnbaum Laboratory

Solutions & reagents needed:
Stanbio Triglyceride Liquicolor Kit (Cat no. 2100-430)
Bicinchoninic Acid Protein Assay kit, Peirce

Triglyceride lysis buffer:
recipe

10 mL

140 mM NaCl

280 μL 5 M NaCl

50 mM Tris-HCl, pH 7.4

500 μL 1 M Tris-HCl, pH 7.4

20% Triton X-100

10 μL Triton X-100

1X Protease inhibitors

400 μL 25X protease inhibitors
8.81 mL H2O

Tissue disruption
1. Prepare fresh triglyceride lysis buffer. Chill on ice.
2. Add 150 μL lysis buffer to each sample.
3. Sonicate each larva/adult 3 times, 10 seconds per time at level 4.5. Keep samples on
Ice between sonication steps.
4. Centrifuge 13,000 rpm, 10 min, 4°C.
5. Transfer supernatant to new tube. Use directly in assay or freeze at –20°C.
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Triglyceride measurement – Stanbio Triglyceride Assay kit.
1. Prepare activated triglyceride reagent. Let sit at room temperature until ready for use.
Each well requires 90 μL. 10 mL of activated reagent is sufficient for a whole 96-well
plate.

10 mL activated triglyceride reagent:
100 μL yellow activator reagent (from eyedropper bottle).
9.9 mL triglyceride reagent

2. Prepare triglyceride standards in Eppendorf tubes.
Concentration

1X PBS

Triglyceride std (2mg/mL stock)

0 μg/mL

40 μL

0 μL

50

39

1

100

38

2

200

36

4

400

32

8

800

24

16

1600

8

32

3. Pipette 10 μL of each standard in triplicate as shown in the template (next page).
4. Add 10-15 μL of each unknown in triplicate as shown in the template.
5. Add 90 μL of activated triglyceride reagent to each well.
6. Incubate at 37°C for 5 min.
7. Read plate at 500 nm.
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Protein measurement – Pierce BCA kit.
Triglyceride lysis buffer interferes with the assay to a small degree, so add triglyceride
lysis buffer to each standard in the same volume used for each unknown.

Typically use 10 or 15 μL lysate per sample.

Data analysis
1. Divide protein and triglyceride concentrations by volume used for each sample to get
μg/μL.
2. Divide triglyceride concentration by protein concentration.
3. Statistics.
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NAD+/NADH Quantification Colorimetric Kit (#K337-100)

Reagent reconstitution:
•

Warm Extraction and Cycling Buffers to RT (store at -4°C or -20°C)

•

Add 220μL NAD Cycling Buffer to NAD Cycling Enzyme Mix. Aliquot volume
needed for each experiment (3 aliquots of 58 μL, store at -80°C)

•

Add 1.2mL ddH2O to Developer. Pipette to mix-do not vortex (store at -20°C
protected from light)

•

Add 200μL DMSO to Standard (store at -20°C)

Sample preparation:
•

Pool 10 decapitated adult male flies

•

Homogenize for 30 pulses in 400μL of Extraction Buffer

•

Vortex for 10 seconds

•

Centrifuge at 14000 rpm for 5 minutes

•

Transfer supernatant to a new tube

•

Aliquot 200μL of homogenate into a new tube and heat to 60C for 30 minutes to
decompose NAD. Cool immediately on ice and spin if precipitate occurs.

•

Load 50μL of the original and heated samples in duplicate

Standard curve preparation:
•

Dilute 10μL of NADH standard in 990μL Extraction Buffer

•

Load the following reagents in duplicate
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NADH Standard(μL)

Extraction Buffer(μL)

0

100

4

96

8

92

12

88

16

84

20

80

Plate Procedure:
•

Prepare Reaction Mix (98μL Cycling Buffer + 2μL Cycling Enzyme Mix)

•

Add 100μL Reaction Mix into each well

•

Incubate for 5 minutes on shaker at room temperature

•

Add 10μL NADH Developer into each well

•

Read plate at 450nm, cycle at room temperature for 1-4 hours at room
temperature (can read multiple times)

•

Stop reaction with 10μL Stop Solution. Color will be stable for 48 hours.

NAD/NADH ratio: (NADtotal-NADH)/NADH
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